

REVIEW

Open Access



Targeting mitochondria with natural polyphenols for treating Neurodegenerative Diseases: a comprehensive scoping review from oxidative stress perspective

Yueyue Guan^{1†}, Lei Li^{2†}, Rui Yang¹, Yun Lu^{3*} and Jun Tang^{1*}

Abstract

Neurodegenerative diseases are a class of conditions with widespread detrimental impacts, currently lacking effective therapeutic drugs. Recent studies have identified mitochondrial dysfunction and the resultant oxidative stress as crucial contributors to the pathogenesis of neurodegenerative diseases. Polyphenols, naturally occurring compounds with inherent antioxidant properties, have demonstrated the potential to target mitochondria and mitigate oxidative stress. This therapeutic potential has garnered significant attention in recent years. Investigating the mitochondrial targeting capacity of polyphenols, their role in functional regulation, and their ability to modulate oxidative stress, along with exploring novel technologies and strategies for modifying polyphenol compounds and their formulations, holds promise for providing new avenues for the treatment of neurodegenerative diseases.

Keywords Neurodegenerative disease, Polyphenols, Mitochondria, Oxidative stress

Introduction

Neurodegenerative diseases, also known as neurodegenerative disorders, are conditions characterized by the progressive degeneration of neuronal cells in the brain and spinal cord [1, 2]. Comprising neurons with diverse functionalities such as motor control, sensory processing,

and decision-making, the cells within the brain and spinal cord do not regenerate [3]. Consequently, excessive damage can be devastating and irreversible [4]. These diseases result from losing neurons or their myelin sheaths, worsening and leading to functional impairments [5, 6]. Neurodegenerative diseases encompass conditions such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), Parkinson's disease, Alzheimer's disease, Huntington's disease, multiple system atrophy, tauopathies, and prion diseases [7]. Globally, an estimated 55 million people were living with dementia in 2019, a number projected to increase to 139 million by 2050. Currently, only a handful of drugs are available for some neurodegenerative diseases. Thus, there is an urgent need to elucidate the mechanisms underlying neurodegenerative diseases and develop corresponding small-molecule therapeutics [8, 9].

Research indicates that oxidative stress and inflammation are two primary factors contributing to

[†]Yueyue Guan and Lei Li contributed equally to this work.

*Correspondence:

Yun Lu

luyun999@126.com

Jun Tang

tangjun@cqctcm.edu.cn

¹ Department of Encephalopathy, Chongqing Hospital of Traditional Chinese Medicine, Chongqing 400021, China

² Department of Anorectal Surgery, Hospital of Chengdu University of Traditional Chinese Medicine and Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China

³ Department of Emergency Medicine, Hospital of Chengdu University of Traditional Chinese Medicine and Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China



neurodegeneration [10, 11]. The most common form of cell death in neurodegeneration occurs through the intrinsic mitochondrial apoptotic pathway [12, 13]. This pathway regulates the activation of caspase-9 by modulating the release of cytochrome c into the mitochondrial intermembrane space [14, 15]. Reactive oxygen species (ROS) are one of the byproducts of oxidative metabolism in cells, possessing active oxidative capabilities [16]. They mainly originate from pathways such as the mitochondrial respiratory chain, endoplasmic reticulum, and oxidases [17]. Excessive ROS can be reduced by cellular antioxidant systems, such as the Nrf2-mediated antioxidant system, GSH, and NADPH [18, 19]. Under physiological conditions, the production and reduction of ROS form a balance known as redox homeostasis [20, 21]. However, under pathophysiological conditions, the production of ROS far exceeds reduction, leading to damage to biomolecules and mitochondria, thus causing cellular dysfunction and even death [22, 23]. This imbalance between oxidation and reduction is known as oxidative stress [24, 25]. Excessive generation of ROS is a hallmark feature of all neurodegenerative diseases [26, 27].

Mitochondria, often described as the powerhouses of the cell, play a vital role in ensuring cellular vitality through their involvement in energy production and metabolic regulation [28, 29]. Mitochondrial dysfunction caused by oxidative stress is closely associated with the occurrence and development of neurodegenerative diseases [30, 31]. ROS are normal byproducts of mitochondrial respiratory chain activity [32, 33]. The concentration of ROS is mitigated by mitochondrial antioxidants such as manganese superoxide dismutase (SOD2) and glutathione peroxidase [34, 35]. Overproduction of ROS is a central feature in all neurodegenerative diseases [36, 37]. In addition to ROS generation, mitochondria also participate in vital functions such as calcium homeostasis, programmed cell death (PCD), mitochondrial fission and fusion, lipid composition of the mitochondrial membrane, and permeability transition of mitochondria [38, 39]. For example, axonal swelling and spheroids have been observed across neurodegenerative diseases [40, 41], suggesting that defective axons are not only present in affected neurons and may also result from the accumulation of organelles, causing specific pathological damage. Axonal transport can be disrupted through various mechanisms, including damage to motor proteins and cytoplasmic dynein, microtubules, cargo, and mitochondria [42, 43]. When severely disrupted axonal transport, it often triggers a degenerative pathway known as Wallerian-like degeneration. Mitochondrial disorders contributing to neurodegeneration may involve all these functions to some extent [44]. Evidence suggests that mitochondrial dysfunction and oxidative stress play a

causal role in the pathogenesis of neurodegenerative diseases (Fig. 1).

Polyphenols, also known as polyhydroxyphenols, constitute a class of naturally occurring phenolic compounds widely distributed in plant tissues, characterized by their abundant content and diverse structures [45, 46]. Additionally, polyphenols can be obtained through synthesis or semi-synthesis, distinguished by numerous phenolic structural units within their molecules [47]. The quantity and characteristics of these phenolic structures define polyphenols' unique physicochemical and biological properties, including but not limited to their metabolic, toxicological, and therapeutic attributes [48, 49]. Polyphenols can be broadly categorized into four major classes: phenolic acids, flavonoids, stilbenes, and lignans [50, 51]. Since the late twentieth century, polyphenols have garnered increasing attention. Numerous epidemiological studies suggest that diets rich in polyphenols contribute to reducing the incidence of chronic inflammatory diseases, including but not limited to cardiovascular diseases [52, 53], type 2 diabetes [54, 55], neurodegenerative diseases [56, 57], osteoporosis [58, 59], and cancer [60, 61]. Research also indicates that polyphenols aid in enhancing brain function and preventing the onset of neurodegenerative diseases such as Alzheimer's disease [62]. For instance, elderly individuals who regularly consume curcumin-containing curry show improved cognitive function compared to their peers with lower consumption [63]. Additionally, it has been found that elderly individuals who frequently drink green tea exhibit superior brain function compared to those consuming coffee or black tea [64]. These benefits may be attributed to the antioxidant effects of polyphenols and their improvement of cerebral blood flow [65, 66]. The antioxidant mechanisms of polyphenols primarily involve neutralizing free radicals by electron and/or hydrogen atom transfer, reducing metal-dependent hydroxyl radicals via chelation mechanisms, mitigating mitochondrial dysfunction to reduce cell apoptosis, and enhancing the endogenous antioxidant enzyme defense system by activating nuclear factor E2-related factor 2 (NRF2), among other pathways [67, 68]. These actions can inhibit reactive oxygen species and their associated inflammatory responses, exerting neuroprotective effects [69, 70]. Therefore, research on polyphenols and the development of small-molecule compounds and formulations holds promise for providing new therapeutic strategies for the treatment of neurodegenerative diseases.

This review aims to explore the role of polyphenols in regulating mitochondria and to introduce innovative approaches for harnessing the therapeutic potential of polyphenols in mitochondrial regulation. A systematic methodology was employed to assess the role of




Fig. 1 Mitochondrial dysfunction in the formation of neurodegenerative diseases. Mitochondrial dysfunction is closely associated with the onset and progression of neurodegenerative diseases. Abnormalities in mitochondrial biogenesis, fission/fusion, damage, and ATP synthesis are frequently implicated in the progression of neurodegenerative disorders, contributing to the pathogenesis of diseases such as Parkinson's disease, Alzheimer's disease, Huntington's disease, and amyotrophic lateral sclerosis

polyphenols in mitochondrial regulation. A comprehensive search strategy was utilized to identify relevant studies published in peer-reviewed journals from 2019 to 2024. Studies were selected based on their focus on polyphenols and mitochondrial regulation, with priority given to clinical trials and in vitro experiments. A structured search was conducted across multiple databases, including PubMed, Scopus, and Web of Science, using keywords such as "polyphenols," "mitochondrial regulation," and "oxidative stress." Studies published between 2019 and 2024 were reviewed, and only those with relevant methodologies and outcomes were

retained. All study inclusion and exclusion decisions were independently reviewed by two researchers, with disagreements resolved by a third reviewer. The search strategy was pre-registered to minimize the risk of selection bias.

The antioxidant effects of natural polyphenols in neurodegenerative diseases

Classification and chemical structures of natural polyphenols and their antioxidant properties

Polyphenols are a class of secondary metabolites widely present in plants, primarily including four major groups:

phenolic acids, flavonoids, lignans, and stilbenes [71, 72]. These compounds exhibit diverse structures but commonly feature multiple phenolic groups, which form the chemical basis for their antioxidant properties [72, 73]. Among polyphenols, flavonoids represent the largest and most renowned group, encompassing a wide variety of compounds such as flavones, flavonols, flavanols, flavanones, isoflavones, anthocyanins, and proanthocyanidins [74, 75]. These compounds are rich in dietary sources; for example, catechins are predominantly found in tea and fruits, hesperetin is abundant in citrus fruits, and anthocyanins are widespread in red fruits and berries [76, 77]. These flavonoid compounds possess potent antioxidant capabilities, effectively scavenging free radicals and reducing oxidative stress to protect cellular integrity.

Phenolic acids, encompassing benzoic acid and cinnamic acid derivatives, also exhibit outstanding antioxidant characteristics [78, 79]. They are primarily sourced from tea, red fruits, black radishes, and onions [80, 81]. These compounds can interrupt oxidative chain reactions by stabilizing free radicals through their phenolic hydroxyl groups [82, 83]. Lignans, a class of polyphenols derived from the amino acid phenylalanine found in flaxseeds and other grains, demonstrate robust antioxidant and anti-inflammatory properties, counteracting inflammation and oxidative stress within the body [84, 85]. Representative substances within the stilbene group, such as resveratrol, have been extensively studied for their anticancer and cardiovascular protective effects [86, 87].

Overall, the antioxidant activity of polyphenols primarily operates through the following mechanisms: firstly, they directly scavenge detrimental free radicals, reducing cellular damage and aging processes; secondly, polyphenols can upregulate the body's antioxidant enzyme systems, such as superoxide dismutase and glutathione peroxidase, further enhancing the antioxidant defense system; finally, polyphenols also participate in regulating various signaling pathways to counteract inflammatory responses induced by oxidative stress. Therefore, polyphenols hold a significant position in food science and demonstrate tremendous potential in medicine and pharmacology.

Impact of natural polyphenols on mitochondrial Function in neurodegenerative diseases

The targeted action of natural polyphenols on mitochondria

Polyphenols, naturally occurring compounds found in plants, have been identified as potent modulators of mitochondrial function, offering protective effects against oxidative stress and enhancing cellular energy metabolism. Polyphenols interact with various molecular targets within the mitochondria, leading to improved functionality [88, 89]. These interactions enhance ATP

production efficiency and reduced ROS generation, thereby shielding cells from oxidative stress damage [90, 91]. For instance, polyphenolic substances such as resveratrol have demonstrated targeted effects on mitochondrial biogenesis [92]. This improvement in mitochondrial function is facilitated by activating key pathways such as SIRT1/PGC-1 α , critical for enhancing mitochondrial DNA replication and transcription, both essential processes for efficient cellular energy production [93, 94]. Additionally, curcumin, a polyphenolic compound found in turmeric, enhances mitochondrial function through its potent antioxidant effects [95]. It participates in the regulation of mitochondrial dynamics, including fusion and division processes, which are vital for maintaining mitochondrial integrity and function [96]. The regulation of these dynamics helps prevent mitochondrial dysfunction that often leads to cell death and has been implicated in various age-related diseases [97, 98]. Another powerful polyphenol, epigallocatechin gallate (EGCG), found in green tea, has been shown to elevate mitochondrial oxidative phosphorylation capacity [99]. This increase in capacity directly correlates with enhanced cellular energy production, which is crucial for maintaining the energy demands of the cell [100, 101]. EGCG also protects against mitochondrial damage by scavenging free radicals and reducing oxidative stress within the cell [102]. Furthermore, polyphenols like quercetin and catechins have been observed to influence mitochondrial potential and help maintain the optimal electron transport chain function, which is crucial for ATP production [103, 104]. These compounds enhance the bioenergetic efficiency of mitochondria, reducing the leakage of electrons, which can form harmful ROS.

In summary, the interaction of polyphenols with mitochondrial components helps boost ATP production and also plays a protective role by mitigating oxidative stress (Fig. 2). This dual function is critical in maintaining cellular health and preventing the onset of mitochondrial-related diseases. Research into how polyphenols enhance mitochondrial function continues to be a promising area for therapeutic development, especially in aging and associated diseases where mitochondrial dysfunction is a common factor.

Regulation of mitochondrial function by natural polyphenols

Natural polyphenolic substances enhance mitochondrial capacity and efficiency [105, 106]. They benefit by modulating crucial signaling pathways and activating transcription factors involved in mitochondrial biogenesis [107]. Among these transcription factors are NRF1/2 and Estrogen-Related Receptors (ERRs), which play central roles in mitochondrial function and energy production [108, 109]. By engaging these pathways, polyphenols help




Fig. 2 The category of polyphenols and the effect on mitochondria. **A** Polyphenols can be categorized into phenolic acids, flavonoids, stilbenes, and lignans. **B** Polyphenols can influence mitochondrial function through various mechanisms. For example, curcumin and quercetin activate antioxidant systems to inhibit ROS accumulation, while resveratrol promotes the expression of mitochondrial DNA by enhancing PGC-1 α , thereby stimulating mitochondrial biogenesis. Additionally, EGCG and quercetin protect the electron transport chain (ETC), facilitating ATP synthesis in mitochondria. Moreover, resveratrol activates the AMPK pathway, and quercetin promotes autophagy, both of which contribute to the enhancement of mitochondrial biological function

maintain optimal energy utilization and reduce the cellular impact of aging and related diseases.

Resveratrol is one of the most studied polyphenolic compounds, renowned for its role as a SIRT1 activator and optimizing energy utilization by influencing the AMP-activated protein kinase (AMPK) pathway [110, 111]. AMPK acts as an energy sensor within cells, promoting energy production in response to cellular stress and nutrient deprivation [112]. Through activation of SIRT1 and AMPK, resveratrol enhances mitochondrial function, increases ATP production, and improves metabolic efficiency, making it an effective agent against age-related decline in mitochondrial function [113].

Curcumin, another powerful polyphenolic compound found in turmeric, extends its benefits beyond mitochondrial regulation. It enhances the cellular antioxidant response by activating the NRF2 pathway [114]. NRF2 is a critical element in the cellular defensive strategy against oxidative stress, regulating the expression of antioxidant proteins that protect against oxidative damage triggered by injury and inflammation [115, 116]. Through these mechanisms, curcumin supports mitochondrial integrity and prevents the functional decline that accompanies neurodegenerative disease [117]. Quercetin, a flavonoid abundant in fruits and vegetables, contributes to mitochondrial health by activating NRF1 and Peroxisome

Proliferator-Activated Receptor Gamma (PPAR γ) [118]. These factors are crucial for mitochondrial biogenesis and function, facilitating the increase in both the number and efficiency of mitochondria. By enhancing mitochondrial biogenesis, quercetin improves cellular energy status, vital for reducing fatigue, boosting physical performance, and mitigating the effects of aging.

The interaction between natural polyphenols and mitochondrial oxidative stress

In addition to individual effects, polyphenols collectively support cellular health through synergistic actions. They stabilize mitochondrial membranes, enhance electron transport chain efficiency, and reduce electron leakage, which can lead to excessive production of ROS. This reduction in ROS is essential for preventing oxidative damage, which is a major cause of cellular aging and dysfunction.

Epicatechin gallate is particularly effective at reducing oxidative stress [119, 120]. It does so not only by directly scavenging free radicals but also by modulating the activity of various antioxidant enzymes such as SOD and glutathione peroxidase [120, 121]. These enzymes are critical in converting harmful ROS into less reactive molecules, thereby protecting cells from oxidative damage.

The protective effects of polyphenols on mitochondrial DNA are significant, given that mitochondrial DNA (mtDNA) is more susceptible to oxidative damage than nuclear DNA [122]. This susceptibility stems from the proximity of mtDNA to the inner mitochondrial membrane, where most ROS are generated, and from its limited protective histone proteins and less efficient DNA repair mechanisms [123]. By preserving mtDNA integrity, polyphenols help ensure the proper functioning of mitochondria and the longevity of cells [124]. Moreover, the cumulative effects of polyphenols in modulating oxidative stress go beyond individual antioxidant activities. They stimulate signaling pathways that enhance the cell's intrinsic antioxidative defenses, leading to a more robust response against oxidative stress [125]. This includes the upregulation of NRF2, a key transcription factor that orchestrates the expression of multiple antioxidative proteins and detoxifying enzymes [126].

Polyphenols regulate downstream events of mitochondrial oxidative stress in neurodegenerative diseases

Oxidative stress can modulate various intracellular pathways [127]. On one hand, oxidative stress can directly induce redox damage to DNA and proteins, leading to gene mutations or protein degradation, thereby disrupting key signaling molecules and altering cellular functions [128, 129]. On the other hand, oxidative stress can result in redox modifications of biomolecules within the

cell; for instance, free cysteine residues in proteins may undergo oxidation to form disulfide bonds and other redox modifications, which can change protein activity and impact the activation of signaling pathways [130, 131]. The interaction between polyphenols and mitochondria can also regulate the activation of various downstream pathways in cells through ROS generated by mitochondrial oxidative stress, thereby influencing the onset and progression of neurodegenerative diseases (Fig. 3).

Polyphenol modulation of oxidative stress-induced genetic mutations

Oxidative stress can damage biomolecules within cells, including genomic DNA, which can result in genetic mutations [128, 132, 133]. The brain consumes as much as one-fifth of the oxygen, and reactive oxygen species generated by oxidative metabolism are the main source of DNA damage in the brain [134, 135]. Many neurodegenerative diseases are caused by genetic mutations, most of which are located in entirely unrelated genes [136, 137]. Across many different diseases, mutated genes share a common feature: the repetition of CAG nucleotide triplets [138, 139]. CAG encodes the amino acid glutamine. Repeated CAG sequences result in the formation of polyglutamine (polyQ) tracts. Diseases associated with such mutations are termed trinucleotide repeat disorders. PolyQ repeats typically lead to dominant disease mechanisms [140]. Additional glutamine residues can confer toxicity through various mechanisms, including irregular protein folding and degradation pathways, altered subcellular localization, and aberrant interactions with other cellular proteins [141]. PolyQ research often employs various animal models due to a well-defined trigger factor—repeat expansion [142]. Numerous studies have shown polyphenolic compounds to alleviate gene mutations and the onset of degenerative diseases by combating oxidative stress, thereby mitigating the inflammatory microenvironment [143, 144]. Extensive studies have been conducted using models such as the *C. elegans* [145], *Drosophila* [146], mice [147], and non-human primate models [148].

Polyphenol-mediated epigenetics regulated by oxidative stress

Oxidative stress is a pivotal factor influencing epigenetic mechanisms, which play significant roles in the pathogenesis of neurodegenerative diseases [127, 149, 150]. Oxidative stress arises when excess ROS disrupts cellular balance, overwhelming the antioxidant defenses [151]. ROS can modify the structure and function of cellular macromolecules, including DNA, proteins, and lipids [152, 153]. At the epigenetic level, oxidative stress




Fig. 3 Mitochondria-induced oxidative stress promotes progression of neurodegenerative diseases. **A** Mitochondrial dysregulation often involves disturbances in lipid and glucose metabolism, abnormalities in the electron transport chain, and dysregulation of calcium signaling, all of which contribute to mitochondrial homeostasis imbalance. **B** This imbalance leads to the accumulation of ROS and can promote cell death. Specifically, oxidative stress resulting from mitochondrial dysfunction can affect processes such as DNA repair, epigenetics, protein folding, and protein degradation, ultimately triggering the onset of programmed cell death

affects DNA methylation patterns, histone modifications, and non-coding RNA expression [131, 154, 155]. Therefore, polyphenols can also influence the epigenetic status within cells by regulating ROS levels, thereby affecting the progression of neurodegenerative diseases [156, 157].

DNA methylation, a critical epigenetic modification involving adding a methyl group to the 5' position of cytosine, is particularly susceptible to oxidative stress [158, 159]. ROS can induce hypomethylation by directly damaging DNA or affecting DNA methyltransferases (DNMTs) activity [160]. This alteration in DNA methylation status can lead to aberrant gene expression, including the dysregulation of genes involved in apoptosis, cell cycle control, and neuronal function [161]. Natural products like curcumin, quercetin, and resveratrol exhibit specific effects by modulating epigenetic processes, particularly DNA methylation, which can modulate downstream gene expression and disease progression [162, 163].

Histone modifications are also affected by oxidative stress [164]. ROS can alter histone acetylation and methylation statuses, influencing chromatin structure and gene expression [165]. For instance, oxidative stress increases histone acetylation, leading to a more relaxed chromatin structure and increased transcriptional activity [166–168]. Conversely, changes in histone methylation can either activate or repress transcription depending on the specific residues and types of modifications affected. Polyphenols, through their oxidized forms, can bind to histones and regulate histone modifications. This interaction, involving a variety of polyphenol-derived compounds, contributes to the chemoprotective functions of dietary polyphenols [169, 170].

Non-coding RNAs, including microRNAs (miRNAs), are another target of oxidative stress [171]. ROS can modulate the expression of miRNAs, which in turn regulate gene expression post-transcriptionally [172, 173]. Changes in miRNA levels affect protein synthesis and cellular pathways critical in neurodegenerative diseases, influencing neuronal survival and function [174]. For instance, curcumin can modulate miRNA activity to regulate key processes like autophagy and inflammation, offering a promising approach to slowing Alzheimer's disease progression by regulating miRNA expression [175, 176].

Polyphenol interventions in oxidative stress and protein misfolding

The spatial conformation of proteins is crucial for their biological functions, and protein folding plays a key role in the protein synthesis process [177, 178]. Protein folding typically occurs in the endoplasmic reticulum, where the endoplasmic reticulum also conducts protein quality

control [179, 180]. Oxidative stress plays a crucial role in regulating protein folding and misfolding, processes intimately linked to the pathogenesis of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis [129, 181]. ROS can directly modify proteins' chemical structure by oxidizing amino acids, leading to aberrant covalent modifications such as carbonylation, nitration, and oxidation of specific residues [182, 183]. These oxidative modifications can result in misfolded protein conformations and the exposure of hydrophobic patches, which are prone to aggregation [184]. Furthermore, oxidative stress can overwhelm the protein quality control systems, including the ubiquitin–proteasome system and autophagy, impairing their ability to effectively degrade misfolded or damaged proteins [185, 186].

In neurodegenerative diseases, the accumulation of misfolded proteins is a hallmark feature [187, 188]. For example, in Alzheimer's disease, oxidative stress is implicated in the abnormal folding and aggregation of amyloid-beta peptides and tau proteins, forming plaques and neurofibrillary tangles, respectively [189, 190]. Similarly, in Parkinson's disease, oxidative modifications contribute to the misfolding of alpha-synuclein, leading to the formation of Lewy bodies [191, 192]. These protein aggregates exert toxic effects on neurons, leading to cellular dysfunction and death [193]. Polyphenols, such as resveratrol and green tea polyphenols, can modulate oxidative stress and Ca^{2+} signaling pathways, reducing ER stress caused by misfolding protein aggregation, which may help alleviate the progression of neurodegenerative diseases [194, 195].

The role of polyphenols in redox control of protein degradation

Parkinson's disease and Huntington's disease are both late-onset disorders associated with the accumulation of toxic proteins within cells [196, 197]. Diseases caused by protein aggregation are termed proteinopathies, primarily driven by the aggregation of cytoplasmic, nuclear, endoplasmic reticulum, and extracellular secreted proteins [198–200]. Recent research indicates that oxidative stress can influence the development and progression of neurodegenerative diseases by modulating protein degradation [201–203]. Eukaryotic cells have two main pathways for removing troublesome proteins or organelles: ubiquitin–proteasome and autophagy–lysosome [204, 205]. Protein ubiquitination with enzymes is crucial for the degradation of many proteins implicated in proteinopathies, including PolyQ expansions and α -synuclein [206, 207].

Polyphenols can regulate the progression of neurodegenerative diseases by modulating key protein

degradation pathways, including ubiquitin–proteasome system (UPS) and autophagy–lysosome pathway (ALP). For instance, polyphenols can modulate the UPS to enhance protein degradation, potentially slowing the progression of neurodegenerative diseases by addressing protein aggregation and improving UPS efficiency [208, 209]. In addition, polyphenols from extra-virgin olive oil, such as oleuropein aglycone and hydroxytyrosol, can activate autophagy to enhance protein degradation and protect against neurodegeneration by reducing oxidative stress, mitochondrial damage, and protein aggregation [210]. By enhancing the efficiency of these pathways, polyphenols promote the clearance of toxic protein aggregates, such as PolyQ expansions and α -synuclein, which are central to diseases like Parkinson's and Huntington's [211, 212]. Through their ability to influence protein degradation, polyphenols help alleviate cellular stress, oxidative damage, and mitochondrial dysfunction, thereby slowing the progression of neurodegenerative disorders [213, 214]. This underscores the therapeutic potential of polyphenols in addressing proteinopathies by enhancing cellular proteostasis.

Programmed cell death regulated by oxidative stress

Programmed cell death (PCD) is any form of cell death mediated by intracellular programs [215]. This process can be activated in neurodegenerative diseases, including Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, and Huntington's disease [216]. PCD observed in neurodegenerative diseases may have direct pathogenic implications; alternatively, PCD may also occur as a result of other injuries or disease processes. The mitochondrial pathway is one of the primary mechanisms by which oxidative stress regulates apoptosis [217–219]. ROS can lead to the permeabilization of the mitochondrial outer membrane, an event largely governed by the Bcl-2 family of proteins [220]. The pro-apoptotic members of this family, such as Bax and Bak, promote this permeabilization, releasing cytochrome c into the cytosol [221–223]. Cytochrome c then binds to apoptotic protease activating factor-1 (Apaf-1) and ATP, which then triggers the formation of the apoptosome, subsequently activating caspase-9 and then caspase-3, culminating in cellular apoptosis [224, 225]. Additionally, oxidative stress influences the endoplasmic reticulum (ER) stress pathway [226, 227]. Accumulating misfolded proteins in the ER under oxidative stress triggers the unfolded protein response (UPR), which can initiate apoptosis if homeostasis is not restored [228, 229]. This involves the activation of CHOP and the ER-resident caspase-12, further propagating the apoptotic signal.

In neurodegenerative diseases, the chronic oxidative stress environment exacerbates the vulnerability

of neurons to apoptosis [230, 231]. The high metabolic demand of neurons and their rich lipid content make them particularly susceptible to oxidative damage [232–234]. For example, in Alzheimer's disease, oxidative stress facilitates the hyperphosphorylation of tau protein and enhances beta-amyloid aggregation, promoting neuronal death [235, 236]. In Parkinson's disease, oxidative stress contributes to the dysfunction and death of dopaminergic neurons in the substantia nigra, a hallmark of the disease pathology [237, 238]. Polyphenols have shown potential in neuroprotection, particularly by reducing naturally occurring neuronal death (NOND) during cerebellar maturation, which is relevant for neurodegenerative diseases. Ex vivo testing demonstrated that PPs such as taxifolin, quercetin-3-O-glucoside, and (+)-catechin effectively reduced neuronal death by up to 72% [239]. These polyphenols likely exert their neuroprotective effects by modulating oxidative stress-induced apoptosis, possibly by inhibiting executioner caspase-3, highlighting their potential for therapeutic applications in neurodegeneration [240].

In conclusion, polyphenols have demonstrated significant neuroprotective potential by modulating oxidative stress-mediated PCD pathways, a key mechanism underlying neurodegenerative diseases. Through attenuation of mitochondrial dysfunction and inhibition of pro-apoptotic signaling cascades—such as the release of cytochrome c and activation of caspases—polyphenols help maintain neuronal survival. Furthermore, they may alleviate endoplasmic reticulum stress and suppress related apoptotic pathways. By reducing oxidative damage and inhibiting executioner caspases, polyphenols effectively mitigate neuronal apoptosis, thereby slowing the progression of disorders such as Alzheimer's and Parkinson's disease.

The application of novel technologies and strategies in neurodegenerative diseases

Due to their antioxidant and anti-inflammatory properties, natural polyphenols have shown potential value in the treatment of neurodegenerative diseases [241]. However, the bioavailability of polyphenolic compounds is typically low, and they often struggle to penetrate the blood–brain barrier, limiting their clinical application [242]. To enhance the neuroprotective effects of natural polyphenols, researchers have developed new technologies and strategies, particularly focusing on their modification, combination, and the use of nanotechnology to facilitate their passage through the blood–brain barrier (Fig. 4).




Fig. 4 Novel Technologies and Strategies in Neurodegenerative Diseases. **A** Glycosylation, methylation, lipidation, and protein modifications can enhance the drugability and pharmacokinetic properties of polyphenols; **B** Co-administration of polyphenols with anti-inflammatory drugs, BDNF, and traditional neurodegenerative disease treatments can significantly improve patient outcomes by reducing adverse effects and enhancing therapeutic efficacy; **C** Novel nanotechnology approaches can significantly improve the ability of polyphenols to cross the blood–brain barrier and exert their pharmacological effects

Novel modification of polyphenols

The chemical modification of polyphenols is a critical area of research aimed at enhancing their stability, bio-availability, and therapeutic efficacy [243]. Despite their potent biological activities, polyphenols often face challenges related to poor solubility, rapid metabolism, and limited systemic availability [244]. To address these issues, researchers are exploring various chemical strategies to modify the fundamental structures of polyphenols to improve their functional properties.

Glycosylation, the process of adding sugar moieties to polyphenols, is one such modification that significantly impacts their solubility and absorption [245, 246]. By attaching one or more glucose units, polyphenols become more water-soluble, which enhances their ability to traverse cellular membranes and improves their bio-availability [247]. Additionally, glycosylation can make polyphenols less susceptible to rapid degradation in the gut and liver, allowing more of the active compound to reach the target tissues [248]. Methylation involves the

addition of methyl groups to the hydroxyl groups of polyphenols. This modification reduces the polarity of polyphenols, enhancing their permeability across lipid membranes and potentially increasing their half-life in the bloodstream [249]. In some cases, methylated polyphenols have shown improved bioactivity, as the methylation can prevent premature oxidation and degradation of the active compounds.

Conjugation with other molecules, such as proteins or lipids, is another strategy used to enhance the therapeutic potential of polyphenols [250]. For example, conjugating polyphenols with lipids can improve lipid solubility, facilitating their incorporation into cell membranes and improving interactions with lipid-rich environments, such as the brain [251]. This is particularly beneficial for targeting neurological disorders where inflammation and oxidative stress are key factors [252]. On the other hand, protein-conjugated polyphenols can be designed to target specific receptors or enzymes within the body, enhancing the specificity and effectiveness of the polyphenol action [253].

Therapeutic combination strategies involving polyphenols

The combined use of polyphenols can produce a synergistic effect, significantly enhancing the treatment of neurodegenerative diseases [254]. Neurodegenerative diseases such as Alzheimer's and Parkinson's are complex and involve multiple pathways, including oxidative stress, mitochondrial dysfunction, and chronic inflammation. Polyphenols, with their multifaceted bioactive properties, are particularly suited for combinatorial strategies to target these pathways effectively [255].

The combination of polyphenols with other therapeutic drugs offers a promising strategy. For example, when polyphenols are used alongside anti-inflammatory agents, such as nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids, they can help reduce the dosage of these drugs required, potentially minimizing side effects while still providing therapeutic benefits [256, 257]. Polyphenols can modulate drug metabolism and increase the bioavailability of these drugs, enhancing their efficacy.

In addition to conventional pharmaceuticals, combining polyphenols with neurotrophic factors (proteins that support the growth, survival, and differentiation of both developing and mature neurons) presents a novel therapeutic avenue [57]. Polyphenols can increase the expression of brain-derived neurotrophic factor (BDNF), a critical molecule involved in neural repair and synaptic plasticity [258]. This increase in BDNF, coupled with the direct application of neurotrophic factors, could synergistically promote neuronal survival and regeneration, offering a powerful approach to combat neurodegeneration

[259]. Furthermore, recent studies have explored the potential of combining polyphenols with current pharmacological treatments for Alzheimer's disease, such as cholinesterase inhibitors [260]. These inhibitors, which aim to increase the levels of neurotransmitters in the brain, could be more effective when used in conjunction with polyphenols, which protect neurons from oxidative damage and improve overall brain health.

Development of nanotechnology for polyphenols

The utilization of nanotechnology significantly enhances the ability of polyphenolic compounds to traverse the blood–brain barrier (BBB), a critical challenge in the treatment of neurological disorders [261]. Nanocarriers such as solid lipid nanoparticles, nanostructured lipid carriers, or polymer nanoparticles efficiently encapsulate polyphenols, protecting them from metabolic degradation and augmenting their permeability across the BBB [262–265]. These nanocarriers enhance the brain delivery of polyphenols through specific pathways such as receptor-mediated transport, thereby improving their therapeutic efficacy in treating neurodegenerative conditions like Alzheimer's and Parkinson's diseases.

Advancements in nanotechnology have paved the way for innovative formulations that improve the solubility and stability of polyphenols, which are often limited by their poor bioavailability [266, 267]. For example, solid lipid nanoparticles are composed of biocompatible and biodegradable materials that can deliver polyphenols directly to neuronal cells, thereby reducing systemic side effects and increasing the concentration of these compounds in the brain [268]. Similarly, nanostructured lipid carriers provide a stable matrix that simultaneously accommodates lipophilic and hydrophilic polyphenols, enhancing their sustained release and biological action within the brain [269].

Polymer nanoparticles, such as those made from PLGA (poly(lactic-co-glycolic acid)), offer additional benefits, including the ability to modify the surface properties to target specific receptors on the BBB [270]. By attaching targeting ligands to the surface of these nanoparticles, it is possible to exploit receptor-mediated endocytosis, a process that facilitates the active transport of polyphenols across the BBB [271]. This targeted delivery system increases the efficiency of polyphenol transport and minimizes the potential for off-target effects [272]. Recent research has also explored using magnetic nanoparticles, which can be directed to specific brain regions using external magnetic fields [273]. This precision targeting enhances the concentration of polyphenols in areas most affected by neurodegenerative processes [274, 275]. Furthermore, the combination of polyphenols with other therapeutic agents within a single nanocarrier can lead to

synergistic effects, potentially reducing the progression of diseases like Alzheimer's more effectively than polyphenols alone [276, 277].

Concluding remarks

In this review, we systematically evaluated the antioxidant properties and mitochondrial-targeting potential of polyphenolic compounds. These compounds show promising biological activities, which may play a crucial role in treating neurodegenerative diseases. However, despite the encouraging evidence, further research is needed to fully understand their mechanisms of action and refine their therapeutic application. Emerging clinical studies underscore the potential of polyphenols in mitigating the neurotoxic side effects associated with a variety of drugs, including chemotherapeutic agents. This protective role enhances patient quality of life and could contribute to better adherence to primary treatments. However, clinical trials focusing on the long-term safety and efficacy of polyphenols, particularly in combination therapies, remain a critical gap in the field.

Future research should focus on advancing the bioavailability and targeting capabilities of polyphenolic compounds. While recent chemical modifications and the development of polyphenol-based nanomedicines have shown promise in enhancing drug targeting and safety, additional studies are needed to optimize these technologies. Specifically, investigations into how these modifications influence pharmacokinetics and pharmacodynamics in the context of neurodegenerative diseases would be valuable. Furthermore, exploring the potential of polyphenol nanomedicines in clinical settings could offer new insights into their practical application. The continued evolution of nanotechnology, combined with a deeper understanding of polyphenols' molecular interactions, could unlock their full therapeutic potential. As research progresses, a more tailored approach to polyphenol therapy could lead to highly effective, personalized treatments for neurodegenerative diseases, addressing current therapeutic challenges and improving patient outcomes. In conclusion, while polyphenolic compounds hold considerable promise for neurodegenerative disease therapy, future research should prioritize refining their delivery mechanisms, expanding clinical evidence, and exploring their role in combination therapies to maximize their therapeutic benefits.

While this review provides valuable insights into the role of polyphenols in modulating oxidative stress and mitochondrial dysfunction in neurodegenerative diseases, several limitations should be acknowledged. First, the majority of the studies discussed are preclinical or ex vivo, and their direct applicability to human clinical settings remains uncertain. The variability in

experimental models, polyphenol dosages, and administration methods further complicates the translation of these findings into therapeutic strategies. Additionally, while the review highlights the potential of polyphenols to modulate redox signaling pathways, the complex interaction between polyphenols and other molecular mechanisms in neurodegenerative diseases is not fully elucidated. Future research should focus on conducting well-designed clinical trials, exploring the optimal therapeutic dosages, and elucidating the broader molecular mechanisms by which polyphenols exert their neuroprotective effects.

Acknowledgements

The authors acknowledge the BioRender (www.biorender.com), as figures in this review were created with BioRender platform.

Author contributions

Y.L. and J.T. conceived the structure of the manuscript. Y.G. and L.L. drafted the initial manuscript and made the figures. R.Y. revised the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by 2024 Bishan District Science and Technology Project in the field of social livelihood "BSKJ2024087"; Chongqing Bayu Qihuang Scholars Support Project (Chongqing Traditional Chinese Medicine [2023] No. 23); Chongqing Municipal Key Specialty Construction Project of Chinese Medicine (Chongqing Chinese Medicine [2022] No. 4); The Sichuan Provincial Natural Science Foundation (NO. 2025ZNSFSC1829) and the Chengdu University of Traditional Chinese Medicine Foundation (NO. MPRC2024014); The Fifth Batch of the National Outstanding Clinical Talents Training Program in Traditional Chinese Medicine (Guo Zhong Yao Ren Jiao Han [2022] No. 1).

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

All authors approved the final manuscript and the submission to this journal.

Competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Received: 5 February 2025 Accepted: 12 May 2025

Published online: 23 May 2025

References

1. Wilson DM 3rd, Cookson MR, Van Den Bosch L, Zetterberg H, Holtzman DM, Dewachter I. Hallmarks of neurodegenerative diseases. *Cell*. 2023;186:693–714.
2. Scheres SHW, Ryskeldi-Falcon B, Goedert M. Molecular pathology of neurodegenerative diseases by cryo-EM of amyloids. *Nature*. 2023;621:701–10.
3. Terreros-Roncal J, Moreno-Jiménez EP, Flor-García M, Rodríguez-Moreno CB, Trinchero MF, Cafini F, Rábano A, Llorens-Martín M. Impact of

- neurodegenerative diseases on human adult hippocampal neurogenesis. *Science*. 2021;374:1106–13.
4. Fyfe I. Neurogenesis altered in multiple neurodegenerative diseases. *Nat Rev Neurol*. 2021;17:726.
 5. Hansson O. Biomarkers for neurodegenerative diseases. *Nat Med*. 2021;27:954–63.
 6. Gerez JA, Riek R. Neurodegenerative diseases distinguished through protein-structure analysis. *Nature*. 2020;578:223–4.
 7. Villoslada P, Baeza-Yates R, Masdeu JC. Reclassifying neurodegenerative diseases. *Nat Biomed Eng*. 2020;4:759–60.
 8. Kampmann M. Molecular and cellular mechanisms of selective vulnerability in neurodegenerative diseases. *Nat Rev Neurosci*. 2024;25:351–71.
 9. Temple S. Advancing cell therapy for neurodegenerative diseases. *Cell Stem Cell*. 2023;30:512–29.
 10. Tesco G, Lomoio S. Pathophysiology of neurodegenerative diseases: an interplay among axonal transport failure, oxidative stress, and inflammation? *Semin Immunol*. 2022;59:101628.
 11. Feng W, Han X, Hu H, Chang M, Ding L, Xiang H, Chen Y, Li Y. 2D vanadium carbide MXene to alleviate ROS-mediated inflammatory and neurodegenerative diseases. *Nat Commun*. 2021;12:2203.
 12. Kleele T, Rey T, Winter J, Zaganelli S, Mahecic D, Perreten Lambert H, Ruberto FP, Nemir M, Wai T, Pedrazzini T, Manley S. Distinct fission signatures predict mitochondrial degradation or biogenesis. *Nature*. 2021;593:435–9.
 13. Park H, Kam TI, Peng H, Chou SC, Mehrabani-Tabari AA, Song JJ, Yin X, Karuppagounder SS, Umanah GK, Rao AVS, et al. PAAN/MIF nuclease inhibition prevents neurodegeneration in Parkinson's disease. *Cell*. 2022;185:1943–1959.e1921.
 14. Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. *Nat Rev Clin Oncol*. 2020;17:395–417.
 15. Attwaters M. Persisting through apoptosis. *Nat Rev Mol Cell Biol*. 2022;23:697.
 16. Bischer AP, Baran TM, Wojtovich AP. Reactive oxygen species drive foraging decisions in *Caenorhabditis elegans*. *Redox Biol*. 2023;67:102934.
 17. Mailloux RJ. An update on methods and approaches for interrogating mitochondrial reactive oxygen species production. *Redox Biol*. 2021;45:102044.
 18. Liu S, Pi J, Zhang Q. Signal amplification in the KEAP1-NRF2-ARE antioxidant response pathway. *Redox Biol*. 2022;54:102389.
 19. Castiglione GM, Xu Z, Zhou L, Duh EJ. Adaptation of the master antioxidant response connects metabolism, lifespan and feather development pathways in birds. *Nat Commun*. 2020;11:2476.
 20. Sies H. Oxidative eustress: on constant alert for redox homeostasis. *Redox Biol*. 2021;41:101867.
 21. Jia M, Qin D, Zhao C, Chai L, Yu Z, Wang W, Tong L, Lv L, Wang Y, Rehwininkel J, et al. Redox homeostasis maintained by GPX4 facilitates STING activation. *Nat Immunol*. 2020;21:727–35.
 22. Foo J, Bellot G, Pervaiz S, Alonso S. Mitochondria-mediated oxidative stress during viral infection. *Trends Microbiol*. 2022;30:679–92.
 23. Wang J, Fröhlich H, Torres FB, Silva RL, Poschet G, Agarwal A, Rappold GA. Mitochondrial dysfunction and oxidative stress contribute to cognitive and motor impairment in FOXP1 syndrome. *Proc Natl Acad Sci U S A*. 2022;119:2112852119.
 24. Gu Y, Han J, Jiang C, Zhang Y. Biomarkers, oxidative stress and autophagy in skin aging. *Ageing Res Rev*. 2020;59:101036.
 25. Griendling KK, Camargo LL, Rios FJ, Alves-Lopes R, Montezano AC, Touyz RM. Oxidative stress and hypertension. *Circ Res*. 2021;128:993–1020.
 26. Bai R, Guo J, Ye XY, Xie Y, Xie T. Oxidative stress: The core pathogenesis and mechanism of Alzheimer's disease. *Ageing Res Rev*. 2022;77:101619.
 27. Li B, Ming H, Qin S, Nice EC, Dong J, Du Z, Huang C. Redox regulation: mechanisms, biology and therapeutic targets in diseases. *Signal Transduct Target Ther*. 2025;10:72.
 28. Iwata R, Casimir P, Erkol E, Boubakar L, Planque M, Gallego López IM, Ditekowska M, Gaspariunaitė V, Beckers S, Remans D, et al. Mitochondria metabolism sets the species-specific tempo of neuronal development. *Science*. 2023;379:eabn4705.
 29. Suomalainen A, Nunnari J. Mitochondria at the crossroads of health and disease. *Cell*. 2024;187:2601–27.
 30. Chintaluri C, Vogels TP. Metabolically regulated spiking could serve neuronal energy homeostasis and protect from reactive oxygen species. *Proc Natl Acad Sci U S A*. 2023;120:e2306525120.
 31. Zhang Y, Zhang M, Zhu W, Yu J, Wang Q, Zhang J, Cui Y, Pan X, Gao X, Sun H. Succinate accumulation induces mitochondrial reactive oxygen species generation and promotes status epilepticus in the kainic acid rat model. *Redox Biol*. 2020;28:101365.
 32. Billingham LK, Stoolman JS, Vasan K, Rodriguez AE, Poor TA, Szibor M, Jacobs HT, Reczek CR, Rashidi A, Zhang P, et al. Mitochondrial electron transport chain is necessary for NLRP3 inflammasome activation. *Nat Immunol*. 2022;23:692–704.
 33. Nolfi-Donagan D, Braganza A, Shiva S. Mitochondrial electron transport chain: oxidative phosphorylation, oxidant production, and methods of measurement. *Redox Biol*. 2020;37:101674.
 34. Karunakaran U, Elumalai S, Chung SM, Maedler K, Won KC, Moon JS. Mitochondrial aldehyde dehydrogenase-2 coordinates the hydrogen sulphide—AMPK axis to attenuate high glucose-induced pancreatic β -cell dysfunction by glutathione antioxidant system. *Redox Biol*. 2024;69:102994.
 35. Wang Y, Liu Z, Ma J, Xv Q, Gao H, Yin H, Yan G, Jiang X, Yu W. Lycopenene attenuates the inflammation and apoptosis in aristolochic acid nephropathy by targeting the Nrf2 antioxidant system. *Redox Biol*. 2022;57:102494.
 36. George M, Tharakan M, Culbertson J, Reddy AP, Reddy PH. Role of Nrf2 in aging, Alzheimer's and other neurodegenerative diseases. *Ageing Res Rev*. 2022;82:101756.
 37. Goicoechea L, Conde de la Rosa L, Torres S, García-Ruiz C, Fernández-Checa JC. Mitochondrial cholesterol: Metabolism and impact on redox biology and disease. *Redox Biol*. 2023;61:102643.
 38. Monzel AS, Enríquez JA, Picard M. Multifaceted mitochondria: moving mitochondrial science beyond function and dysfunction. *Nat Metab*. 2023;5:546–62.
 39. Bock FJ, Tait SWG. Mitochondria as multifaceted regulators of cell death. *Nat Rev Mol Cell Biol*. 2020;21:85–100.
 40. Lang-Ouellette D, Gruver KM, Smith-Dijk A, Blot FGC, Stewart CA, de Vanssay de Blavous P, Li CH, Van Eitrem C, Rosen C, Faust PL, et al. Purkinje cell axonal swellings enhance action potential fidelity and cerebellar function. *Nat Commun*. 2021;12:4129.
 41. Yuan P, Zhang M, Tong L, Morse TM, McDougal RA, Ding H, Chan D, Cai Y, Grutzendler J. PLD3 affects axonal spheroids and network defects in Alzheimer's disease. *Nature*. 2022;612:328–37.
 42. Jin C, Washimi Y, Yoshida K, Hashizume Y, Yazawa I. Characterization of spheroids in hereditary diffuse leukoencephalopathy with axonal spheroids. *J Neurol Sci*. 2015;352:74–8.
 43. Mejia Maza A, Carmen-Orozco RP, Carter ES, Dávila-Villacorta DG, Castillo G, Morales JD, Mamani J, Gavidia CM, Alroy J, Sterling CR, et al. Axonal swellings and spheroids: a new insight into the pathology of neurocysticercosis. *Brain Pathol*. 2019;29:425–36.
 44. Esteras N, Kopach O, Maiolino M, Lariccia V, Amoroso S, Qamar S, Wray S, Rusakov DA, Jaganjac M, Abramov AY. Mitochondrial ROS control neuronal excitability and cell fate in frontotemporal dementia. *Alzheimers Dement*. 2022;18:318–38.
 45. Pi X, Sun Y, Cheng J, Fu G, Guo M. A review on polyphenols and their potential application to reduce food allergenicity. *Crit Rev Food Sci Nutr*. 2023;63:10014–31.
 46. Luca SV, Macovei I, Bujor A, Miron A, Skalik-Woźniak K, Aprotosoae AC, Trifan A. Bioactivity of dietary polyphenols: the role of metabolites. *Crit Rev Food Sci Nutr*. 2020;60:626–59.
 47. Zhang Y, Tian X, Teng A, Li Y, Jiao Y, Zhao K, Wang Y, Li R, Yang N, Wang W. Polyphenols and polyphenols-based biopolymer materials: regulating iron absorption and availability from spontaneous to controllable. *Crit Rev Food Sci Nutr*. 2023;63:12341–59.
 48. Liu Y, Wang L, Zhao L, Zhang Y. Structure, properties of gossypol and its derivatives from physiological activities to drug discovery and drug design. *Nat Prod Rep*. 2022;39:1282–304.
 49. Xue H, Gao Y, Wu L, Cai X, Liao J, Tan J. Research progress in extraction, purification, structure of fruit and vegetable polysaccharides and their interaction with anthocyanins/starch. *Crit Rev Food Sci Nutr*. 2023;65:1–26.

50. Chiorcea-Paquim AM, Enache TA, De Souza GE, Oliveira-Brett AM. Natural phenolic antioxidants electrochemistry: towards a new food science methodology. *Compr Rev Food Sci Food Saf*. 2020;19:1680–726.
51. Wu M, Luo Q, Nie R, Yang X, Tang Z, Chen H. Potential implications of polyphenols on aging considering oxidative stress, inflammation, autophagy, and gut microbiota. *Crit Rev Food Sci Nutr*. 2021;61:2175–93.
52. Jenkins DJA, Kendall CWC, Sievenpiper JL. Plant polyphenols lignans and cardiovascular disease. *J Am Coll Cardiol*. 2021;78:679–82.
53. Wan H, Li Y, Qin Y, An Y, Yan H, Liu X, Zhang H, Hu C, Li L, Fu D, et al. Polyphenol-mediated sandwich-like coating promotes endothelialization and vascular healing. *Biomaterials*. 2023;302:122346.
54. Tveter KM, Mezhibovsky E, Wu Y, Roopchand DE. Bile acid metabolism and signaling: emerging pharmacological targets of dietary polyphenols. *Pharmacol Ther*. 2023;248:108457.
55. Visvanathan R, Williamson G. Citrus polyphenols and risk of type 2 diabetes: evidence from mechanistic studies. *Crit Rev Food Sci Nutr*. 2023;63:2178–202.
56. Wang J, Zhang J, Yu ZL, Chung SK, Xu B. The roles of dietary polyphenols at crosstalk between type 2 diabetes and Alzheimer's disease in ameliorating oxidative stress and mitochondrial dysfunction via PI3K/Akt signaling pathways. *Ageing Res Rev*. 2024;99:102416.
57. Moradi SZ, Jalili F, Farhadian N, Joshi T, Wang M, Zou L, Cao H, Farzaei MH, Xiao J. Polyphenols and neurodegenerative diseases: focus on neuronal regeneration. *Crit Rev Food Sci Nutr*. 2022;62:3421–36.
58. Bellavia D, Caradonna F, Dimarco E, Costa V, Carina V, De Luca A, Raimondi L, Fini M, Gentile C, Giavaresi G. Non-flavonoid polyphenols in osteoporosis: preclinical evidence. *Trends Endocrinol Metab*. 2021;32:515–29.
59. Martiniakova M, Babikova M, Mondockova V, Blahova J, Kovacova V, Omelka R. The role of macronutrients, micronutrients and flavonoid polyphenols in the prevention and treatment of osteoporosis. *Nutrients*. 2022;14:523.
60. Li F, Qasim S, Li D, Dou QP. Updated review on green tea polyphenol epigallocatechin-3-gallate as a cancer epigenetic regulator. *Semin Cancer Biol*. 2022;83:335–52.
61. Messaoudene M, Pidgeon R, Richard C, Ponce M, Diop K, Benlaifaoui M, Nolin-Lapalme A, Cauchois F, Malo J, Belkaid W, et al. A natural polyphenol exerts antitumor activity and circumvents anti-PD-1 resistance through effects on the gut microbiota. *Cancer Discov*. 2022;12:1070–87.
62. Li Y, Peng Y, Shen Y, Zhang Y, Liu L, Yang X. Dietary polyphenols: regulate the advanced glycation end products-RAGE axis and the microbiota-gut-brain axis to prevent neurodegenerative diseases. *Crit Rev Food Sci Nutr*. 2023;63:9816–42.
63. Ng TP, Nyunt SZ, Gao Q, Gwee X, Chua DQL, Yap KB. Curcumin-rich curry consumption and life expectancy: Singapore longitudinal ageing study. *Geroscience*. 2024;46:969–80.
64. Mancini E, Beglinger C, Drewe J, Zanchi D, Lang UE, Borgwardt S. Green tea effects on cognition, mood and human brain function: a systematic review. *Phytomedicine*. 2017;34:26–37.
65. Joris PJ, Mensink RP, Adam TC, Liu TT. Cerebral blood flow measurements in adults: a review on the effects of dietary factors and exercise. *Nutrients*. 2018;10:530.
66. Wood E, Hein S, Mesnage R, Fernandes F, Abhayaratne N, Xu Y, Zhang Z, Bell L, Williams C, Rodriguez-Mateos A. Wild blueberry (poly)phenols can improve vascular function and cognitive performance in healthy older individuals: a double-blind randomized controlled trial. *Am J Clin Nutr*. 2023;117:1306–19.
67. Mu K, Kitts DD. Intestinal polyphenol antioxidant activity involves redox signaling mechanisms facilitated by aquaporin activity. *Redox Biol*. 2023;68:102948.
68. Zhang T, Zhou H, Fu Y, Zhao Y, Yuan Z, Shao Z, Wang Z, Qin M. Short-time hydrothermal treatment of poplar wood for the production of a lignin-derived polyphenol antioxidant. *Chemsuschem*. 2020;13:4478–86.
69. Lin K, Zhou M, Leng C, Tao X, Zhou R, Li Y, Sun B, Shu X, Liu W. Neuroprotective effect of polyphenol extracts from *Terminalia chebula* Retz. against cerebral ischemia-reperfusion injury. *Molecules*. 2022;27:6449.
70. Wan C, Ouyang J, Li M, Rengasamy KRR, Liu Z. Effects of green tea polyphenol extract and epigallocatechin-3-O-gallate on diabetes mellitus and diabetic complications: recent advances. *Crit Rev Food Sci Nutr*. 2024;64:5719–47.
71. Pérez-Jiménez J, Agnani K, Lamuela-Raventós RM, St-Onge MP. Dietary polyphenols and sleep modulation: current evidence and perspectives. *Sleep Med Rev*. 2023;72:101844.
72. Zeng B, Jiang T, Xiong W, Che H, Sun S. Protective properties of polyphenols in food allergy: a review. *Allergy*. 2023;78:1654–6.
73. Jin Q, Liu T, Qiao Y, Liu D, Yang L, Mao H, Ma F, Wang Y, Peng L, Zhan Y. Oxidative stress and inflammation in diabetic nephropathy: role of polyphenols. *Front Immunol*. 2023;14:1185317.
74. Zhong ZX, Zhou S, Liang YJ, Wei YY, Li Y, Long TF, He Q, Li MY, Zhou YF, Yu Y, et al. Natural flavonoids disrupt bacterial iron homeostasis to potentiate colistin efficacy. *Sci Adv*. 2023;9:4205.
75. Rufino AT, Costa VM, Carvalho F, Fernandes E. Flavonoids as antiobesity agents: a review. *Med Res Rev*. 2021;41:556–85.
76. Han S, Luo Y, Liu B, Guo T, Qin D, Luo F. Dietary flavonoids prevent diabetes through epigenetic regulation: advance and challenge. *Crit Rev Food Sci Nutr*. 2023;63:11925–41.
77. Aiello P, Consalvi S, Poce G, Raguzzini A, Toti E, Palmery M, Biava M, Bernardi M, Kamal MA, Perry G, Peluso I. Dietary flavonoids: Nano delivery and nanoparticles for cancer therapy. *Semin Cancer Biol*. 2021;69:150–65.
78. Hewawansa U, Houghton MJ, Barber E, Costa RJS, Kitchen B, Williamson G. Flavonoids and phenolic acids from sugarcane: Distribution in the plant, changes during processing, and potential benefits to industry and health. *Compr Rev Food Sci Food Saf*. 2024;23:e13307.
79. Ji L, Deng H, Xue H, Wang J, Hong K, Gao Y, Kang X, Fan G, Huang W, Zhan J, You Y. Research progress regarding the effect and mechanism of dietary phenolic acids for improving nonalcoholic fatty liver disease via gut microbiota. *Compr Rev Food Sci Food Saf*. 2023;22:1128–47.
80. Supikova K, Kosinova A, Vavrusa M, Koplikova L, François A, Pospisil J, Zatloukal M, Wever R, Hartog A, Gruz J. Sulfated phenolic acids in plants. *Planta*. 2022;255:124.
81. Kiokias S, Proestos C, Oreopoulou V. Phenolic acids of plant origin—a review on their antioxidant activity in vitro (O/W emulsion systems) along with their in vivo health biochemical properties. *Foods*. 2020;9:534.
82. Shamanin VP, Tekin-Cakmak ZH, Gordeeva EI, Karasu S, Pototskaya I, Chursin AS, Pozherukova VE, Ozulku G, Morgounov AI, Sagdic O, Koksel H. Antioxidant capacity and profiles of phenolic acids in various genotypes of purple wheat. *Foods*. 2022;11:2515.
83. Bian X, Xie X, Cai J, Zhao Y, Miao W, Chen X, Xiao Y, Li N, Wu JL. Dynamic changes of phenolic acids and antioxidant activity of Citri Reticulatae Pericarpium during aging processes. *Food Chem*. 2022;373:131399.
84. Jang WY, Kim MY, Cho JY. Antioxidant, anti-inflammatory, anti-menopausal, and anti-cancer effects of lignans and their metabolites. *Int J Mol Sci*. 2022;23:15482.
85. Li Z, Zheng Y, Liu K, Liang Y, Lu J, Li Q, Zhao B, Liu X, Li X. Lignans as multi-targeted natural products in neurodegenerative diseases and depression: recent perspectives. *Phytother Res*. 2023;37:5599–621.
86. Clarke TL, Mostoslavsky R. Resveratrol: friend or foe? *Mol Cell*. 2020;79:705–7.
87. Griñán-Ferré C, Bellver-Sanchis A, Izquierdo V, Corpas R, Roig-Soriano J, Chillón M, Andres-Lacueva C, Somogyvári M, Söti C, Sanfeliu C, Pallàs M. The pleiotropic neuroprotective effects of resveratrol in cognitive decline and Alzheimer's disease pathology: from antioxidant to epigenetic therapy. *Ageing Res Rev*. 2021;67:101271.
88. Bhagani H, Nasser SA, Dakroub A, El-Yazbi AF, Eid AA, Kobeissy F, Pintus G, Eid AH. The mitochondria: a target of polyphenols in the treatment of diabetic cardiomyopathy. *Int J Mol Sci*. 2020;21:4962.
89. Zapata J, Castro-Sepulveda M, Soto-Alarcon S, Alvarez D, Bustamante A, Villarroel G, Gallardo A, Garcia-Diaz DF, Valenzuela R, Echeverria F. Targeting mitochondria for the prevention and treatment of nonalcoholic fatty liver disease: polyphenols as a non-pharmacological approach. *Curr Med Chem*. 2023;30:2977–95.
90. Brimson JM, Prasanth MI, Malar DS, Thitilertdech P, Kabra A, Tencomnao T, Prasansuklab A. Plant polyphenols for aging health: implication from their autophagy modulating properties in age-associated diseases. *Pharmaceuticals (Basel)*. 2021;14:982.
91. Lagoa R, Marques-da-Silva D, Diniz M, Daglia M, Bishayee A. Molecular mechanisms linking environmental toxicants to cancer development:

- significance for protective interventions with polyphenols. *Semin Cancer Biol.* 2022;80:118–44.
92. Shaito A, Al-Mansoor M, Ahmad SMS, Haider MZ, Eid AH, Posadino AM, Pintus G, Giordo R. Resveratrol-mediated regulation of mitochondria biogenesis-associated pathways in neurodegenerative diseases: molecular insights and potential therapeutic applications. *Curr Neuropatharmacol.* 2023;21:184–201.
 93. Zhang J, Li J, Liu Y, Liang R, Mao Y, Yang X, Zhang Y, Zhu L. Effect of resveratrol on skeletal slow-twitch muscle fiber expression via AMPK/PGC-1 α signaling pathway in bovine myotubes. *Meat Sci.* 2023;204:109287.
 94. Liu X, Tang M, He TY, Zhao S, Li HZ, Li Z, Guo YX, Wang XL. Resveratrol improves paclitaxel-induced cognitive impairment in mice by activating SIRT1/PGC-1 α pathway to regulate neuronal state and microglia cell polarization. *Drug Des Devel Ther.* 2023;17:1125–38.
 95. Bagheri H, Ghasemi F, Barreto GE, Rafiee R, Sathyapalan T, Sahebkar A. Effects of curcumin on mitochondria in neurodegenerative diseases. *BioFactors.* 2020;46:5–20.
 96. Jin Z, Chang B, Wei Y, Yang Y, Zhang H, Liu J, Piao L, Bai L. Curcumin exerts chondroprotective effects against osteoarthritis by promoting AMPK/PINK1/Parkin-mediated mitophagy. *Biomed Pharmacother.* 2022;151:113092.
 97. Zia A, Farkhondeh T, Pourbagher-Shahri AM, Samarghandian S. The role of curcumin in aging and senescence: molecular mechanisms. *Biomed Pharmacother.* 2021;134:111119.
 98. Li N, Yan X, Huang W, Chu M, Dong Y, Song H, Peng Y, Shi J, Liu Q. Curcumin protects against the age-related hearing loss by attenuating apoptosis and senescence via activating Nrf2 signaling in cochlear hair cells. *Biochem Pharmacol.* 2023;212:115575.
 99. Lee T, Oh Y, Kim MK, Chong Y. Green Tea Catechol (–)-Epigallocatechin Gallate (EGCG) conjugated with phenylalanine shows enhanced autophagy stimulating activity in human aortic endothelial cells. *Planta Med.* 2023;89:423–32.
 100. Zwolak I. Epigallocatechin gallate for management of heavy metal-induced oxidative stress: mechanisms of action, efficacy, and concerns. *Int J Mol Sci.* 2021;22:4027.
 101. Wu Q, Song J, Gao Y, Zou Y, Guo J, Zhang X, Liu D, Guo D, Bi H. Epigallocatechin gallate enhances human lens epithelial cell survival after UVB irradiation via the mitochondrial signaling pathway. *Mol Med Rep.* 2022;25:87.
 102. Wang Y, Wu J, Wang L, Yang P, Liu Z, Rajput SA, Hassan M, Qi D. Epigallocatechin gallate and glutathione attenuate aflatoxin B(1)-induced acute liver injury in ducklings via mitochondria-mediated apoptosis and the Nrf2 signalling pathway. *Toxins (Basel).* 2022;25:87.
 103. Chen Y, Zhao Y, Miao C, Yang L, Wang R, Chen B, Zhang Q. Quercetin alleviates cyclophosphamide-induced premature ovarian insufficiency in mice by reducing mitochondrial oxidative stress and pyroptosis in granulosa cells. *J Ovarian Res.* 2022;15:138.
 104. Chen B, Zhang W, Lin C, Zhang L. A comprehensive review on beneficial effects of catechins on secondary mitochondrial diseases. *Int J Mol Sci.* 2022;23:11569.
 105. Ferramosca A, Lorenzetti S, Di Giacomo M, Lunetti P, Murrieri F, Capobianco L, Dolce V, Coppola L, Zara V. Modulation of human sperm mitochondrial respiration efficiency by plant polyphenols. *Antioxidants (Basel).* 2021;10:217.
 106. Zhao X, Shi X, Liu Q, Li X. Tea polyphenols alleviates acetochlor-induced apoptosis and necroptosis via ROS/MAPK/NF- κ B signaling in *Ctenopharyngodon idellus* kidney cells. *Aquat Toxicol.* 2022;246:106153.
 107. Kung HC, Lin KJ, Kung CT, Lin TK. Oxidative stress, mitochondrial dysfunction, and neuroprotection of polyphenols with respect to resveratrol in Parkinson's Disease. *Biomedicines.* 2021;9:918.
 108. Divyajanani S, Harithipriya K, Ganesan K, Ramkumar KM. Dietary polyphenols remodel DNA methylation patterns of NRF2 in chronic disease. *Nutrients.* 2023;15:3347.
 109. Gołabek A, Kowalska K, Olejnik A. Polyphenols as a diet therapy concept for endometriosis-current opinion and future perspectives. *Nutrients.* 2021;13:1347.
 110. Zhao Q, Tian Z, Zhou G, Niu Q, Chen J, Li P, Dong L, Xia T, Zhang S, Wang A. SIRT1-dependent mitochondrial biogenesis supports therapeutic effects of resveratrol against neurodevelopment damage by fluoride. *Theranostics.* 2020;10:4822–38.
 111. Jin Y, Liu X, Liang X, Liu J, Liu J, Han Z, Lu Q, Wang K, Meng B, Zhang C, et al. Resveratrol rescues cutaneous radiation-induced DNA damage via a novel AMPK/SIRT7/HMGB1 regulatory axis. *Cell Death Dis.* 2023;13:847.
 112. Lee H, Zandkarimi F, Zhang Y, Meena JK, Kim J, Zhuang L, Tyagi S, Ma L, Westbrook TF, Steinberg GR, et al. Energy-stress-mediated AMPK activation inhibits ferroptosis. *Nat Cell Biol.* 2020;22:225–34.
 113. Pyo IS, Yun S, Yoon YE, Choi JW, Lee SJ. Mechanisms of aging and the preventive effects of resveratrol on age-related diseases. *Molecules.* 2020;25:4649.
 114. Liu C, Rokavec M, Huang Z, Hermeking H. Curcumin activates a ROS/KEAP1/NRF2/miR-34a/b/c cascade to suppress colorectal cancer metastasis. *Cell Death Differ.* 2023;30:1771–85.
 115. Pillai R, Hayashi M, Zavitsanou AM, Papagiannakopoulos T. NRF2: KEAP-ing tumors protected. *Cancer Discov.* 2022;12:625–43.
 116. Li L, Peng P, Ding N, Jia W, Huang C, Tang Y. Oxidative stress, inflammation, gut dysbiosis: what can polyphenols do in inflammatory bowel disease? *Antioxidants (Basel).* 2023;12:967.
 117. Heidari S, Mahdiani S, Hashemi M, Kalalinia F. Recent advances in neurogenic and neuroprotective effects of curcumin through the induction of neural stem cells. *Biotechnol Appl Biochem.* 2020;67:430–41.
 118. Wang M, Wang B, Wang S, Lu H, Wu H, Ding M, Ying L, Mao Y, Li Y. Effect of quercetin on lipids metabolism through modulating the gut microbial and AMPK/PPAR signaling pathway in broilers. *Front Cell Dev Biol.* 2021;9:616219.
 119. Yu J, Song H, Zhou L, Wang S, Liu X, Liu L, Ma Y, Li L, Wen S, Luo Y, et al. (–)-Epicatechin gallate prevented atherosclerosis by reducing abnormal proliferation of VSMCs and oxidative stress of AML 12 cells. *Cell Signal.* 2024;121:111276.
 120. Tan J, Vincken JP, van Zadelhoff A, Hilgers R, Lin Z, de Bruijn WJC. Presence of free gallic acid and gallate moieties reduces auto-oxidative browning of epicatechin (EC) and epicatechin gallate (ECg). *Food Chem.* 2023;425:136446.
 121. Yu J, Li W, Xiao X, Huang Q, Yu J, Yang Y, Han T, Zhang D, Niu X. (–)-Epicatechin gallate blocks the development of atherosclerosis by regulating oxidative stress in vivo and in vitro. *Food Funct.* 2021;12:8715–27.
 122. Grabska-Kobylecka I, Szpakowski P, Król A, Książek-Winiarek D, Kobylecki A, Głabiński A, Nowak D. Polyphenols and their impact on the prevention of neurodegenerative diseases and development. *Nutrients.* 2023;15:3454.
 123. Chung CY, Valdebenito GE, Chacko AR, Duchon MR. Rewiring cell signalling pathways in pathogenic mtDNA mutations. *Trends Cell Biol.* 2022;32:391–405.
 124. Islam F, Islam MM, Khan Meem AF, Nafady MH, Islam MR, Akter A, Mitra S, Alhumaydhi FA, Emran TB, Khusro A, et al. Multifaceted role of polyphenols in the treatment and management of neurodegenerative diseases. *Chemosphere.* 2022;307:136020.
 125. Gebicki JM, Nauser T. Fast antioxidant reaction of polyphenols and their metabolites. *Antioxidants (Basel).* 2021;10:1297.
 126. Chen J, Huang Z, Cao X, Chen X, Zou T, You J. Plant-derived polyphenols as nrf2 activators to counteract oxidative stress and intestinal toxicity induced by deoxynivalenol in Swine: an emerging research direction. *Antioxidants (Basel).* 2022;11:2379.
 127. Wu Z, Qu J, Zhang W, Liu GH. Stress, epigenetics, and aging: unraveling the intricate crosstalk. *Mol Cell.* 2024;84:34–54.
 128. Carvajal-Garcia J, Samadpour AN, Hernandez Viera AJ, Merrikh H. Oxidative stress drives mutagenesis through transcription-coupled repair in bacteria. *Proc Natl Acad Sci U S A.* 2023;120:e2300761120.
 129. Zhang SX, Wang JJ, Starr CR, Lee EJ, Park KS, Zhykibayev A, Medina A, Lin JH, Gorbatyuk M. The endoplasmic reticulum: Homeostasis and crosstalk in retinal health and disease. *Prog Retin Eye Res.* 2024;98:101231.
 130. Bodnar Y, Lillig CH. Cysteinyll and methionyll redox switches: structural prerequisites and consequences. *Redox Biol.* 2023;65:102832.
 131. Qin S, Li B, Ming H, Nice EC, Zou B, Huang C. Harnessing redox signaling to overcome therapeutic-resistant cancer dormancy. *Biochim Biophys Acta Rev Cancer.* 2022;1877:188749.
 132. Chen K, Lu P, Beeraka NM, Sukocheva OA, Madhunapantula SV, Liu J, Sinelnikov MY, Nikolenko VN, Bulygin KV, Mikhaleva LM, et al. Mitochondrial mutations and mitoepigenetics: focus on regulation of

- oxidative stress-induced responses in breast cancers. *Semin Cancer Biol.* 2022;83:556–69.
133. Shu L, Hu C, Xu M, Yu J, He H, Lin J, Sha H, Lu B, Engelender S, Guan M, Song Z. ATAD3B is a mitophagy receptor mediating clearance of oxidative stress-induced damaged mitochondrial DNA. *Embo j.* 2021;40:e106283.
 134. Kuntic M, Oelze M, Steven S, Kröller-Schön S, Stamm P, Kalinovic S, Frenis K, Vujacic-Mirski K, Bayo Jimenez MT, Kvandova M, et al. Short-term e-cigarette vapour exposure causes vascular oxidative stress and dysfunction: evidence for a close connection to brain damage and a key role of the phagocytic NADPH oxidase (NOX-2). *Eur Heart J.* 2020;41:2472–83.
 135. Dionísio PA, Amaral JD, Rodrigues CMP. Oxidative stress and regulated cell death in Parkinson's disease. *Ageing Res Rev.* 2021;67:101263.
 136. de Boer EMJ, Orié VK, Williams T, Baker MR, De Oliveira HM, Polvikowski T, Silsby M, Menon P, van den Bos M, Halliday GM, et al. TDP-43 proteinopathies: a new wave of neurodegenerative diseases. *J Neurol Neurosurg Psychiatry.* 2020;92:86–95.
 137. Burgess RW, Storkebaum E. tRNA dysregulation in neurodevelopmental and neurodegenerative diseases. *Annu Rev Cell Dev Biol.* 2023;39:223–52.
 138. Lieberman AP, Shakkottai VG, Albin RL. polyglutamine repeats in neurodegenerative diseases. *Annu Rev Pathol.* 2019;14:1–27.
 139. Benatar M, Wu J, McHutchison C, Postuma RB, Boeve BF, Petersen R, Ross CA, Rosen H, Arias JJ, Fradette S, et al. Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases. *Brain.* 2022;145:27–44.
 140. Bunting EL, Hamilton J, Tabrizi SJ. Polyglutamine diseases. *Curr Opin Neurobiol.* 2022;72:39–47.
 141. Aviner R, Lee TT, Mastro VB, Li KH, Andino R, Frydman J. Polyglutamine-mediated ribotoxicity disrupts proteostasis and stress responses in Huntington's disease. *Nat Cell Biol.* 2024;26:892–902.
 142. Henriques C, Lopes MM, Silva AC, Lobo DD, Badin RA, Hantraye P, Pereira de Almeida L, Nobre RJ. Viral-based animal models in polyglutamine disorders. *Brain.* 2024;147:1166–89.
 143. Majidinia M, Bishayee A, Yousefi B. Polyphenols: Major regulators of key components of DNA damage response in cancer. *DNA Repair (Amst).* 2019;82:102679.
 144. Angelé-Martínez C, Murray J, Stewart PA, Haines J, Gaertner AAE, Brumaghim JL. Cobalt-mediated oxidative DNA damage and its prevention by polyphenol antioxidants. *J Inorg Biochem.* 2023;238:112024.
 145. Sinnige T, Meisl G, Michaels TCT, Vendruscolo M, Knowles TPJ, Morimoto RI. Kinetic analysis reveals that independent nucleation events determine the progression of polyglutamine aggregation in *C. elegans*. *Proc Natl Acad Sci U S A.* 2021. <https://doi.org/10.1073/pnas.2021888118>.
 146. Breznak SM, Peng Y, Deng L, Kotb NM, Flamholz Z, Rapisarda IT, Martin ET, LaBarge KA, Fabris D, Gavis ER, Rangan P. H/ACA snRNP-dependent ribosome biogenesis regulates translation of polyglutamine proteins. *Sci Adv.* 2023;9:5492.
 147. Hirunagi T, Nakatsuji H, Sahashi K, Yamamoto M, Iida M, Tohno G, Kondo N, Yamada S, Murakami A, Noda S, et al. Exercise attenuates polyglutamine-mediated neuromuscular degeneration in a mouse model of spinal and bulbar muscular atrophy. *J Cachexia Sarcopenia Muscle.* 2024;15:159–72.
 148. Bertoglio D, Weiss AR, Liguore W, Martin LD, Hobbs T, Templon J, Srinivasan S, Dominguez C, Munoz-Sanjuan I, Khetarpal V, et al. In vivo cerebral imaging of mutant huntingtin aggregates using (11)C-CHDI-180R PET in a nonhuman primate model of Huntington disease. *J Nucl Med.* 2023;64:1581–7.
 149. Liu ZY, Song K, Tu B, Lin LC, Sun H, Zhou Y, Li R, Shi Y, Yang JJ, Zhang Y, et al. Crosstalk between oxidative stress and epigenetic marks: new roles and therapeutic implications in cardiac fibrosis. *Redox Biol.* 2023;65:102820.
 150. Peng P, Qin S, Li L, He Z, Li B, Nice EC, Zhou L, Lei YJMO. Epigenetic remodeling under oxidative stress: mechanisms driving tumor metastasis. *Oncology.* 2024;3:e70000.
 151. Lennicke C, Cochemé HM. Redox metabolism: ROS as specific molecular regulators of cell signaling and function. *Mol Cell.* 2021;81:3691–707.
 152. Khan AB, Siddiqui U, Fatima S, Rehman AA, Jairajpuri MA. Protein disulfide isomerase uses thrombin-antithrombin complex as a template to bind its target protein and alter the blood coagulation rates. 2024. *Biosci Rep.* <https://doi.org/10.1042/BSR20231540>.
 153. Meyer AJ, Riemer J, Rouhier N. Oxidative protein folding: state-of-the-art and current avenues of research in plants. *New Phytol.* 2019;221:1230–46.
 154. O'Connor KM, Das AB, Winterbourn CC, Hampton MB. Inhibition of DNA methylation in proliferating human lymphoma cells by immune cell oxidants. *J Biol Chem.* 2020;295:7839–48.
 155. Zhao Y, Fan X, Wang Q, Zhen J, Li X, Zhou P, Lang Y, Sheng Q, Zhang T, Huang T, et al. ROS promote hyper-methylation of NDRG2 promoters in a DNMT5-dependent manner: contributes to the progression of renal fibrosis. *Redox Biol.* 2023;62:102674.
 156. Ghasemi S, Xu S, Nabavi SM, Amirkhani MA, Sureda A, Tejada S, Lorigoiini Z. Epigenetic targeting of cancer stem cells by polyphenols (cancer stem cells targeting). *Phytother Res.* 2021;35:3649–64.
 157. Arora I, Sharma M, Sun LY, Tollefsbol TO. The epigenetic link between polyphenols, aging and age-related diseases. *Genes (Basel).* 2020;11:1094.
 158. Loyfer N, Magenheimer J, Peretz A, Cann G, Bredno J, Klochendler A, Fox-Fisher I, Shabi-Porat S, Hecht M, Pelet T, et al. A DNA methylation atlas of normal human cell types. *Nature.* 2023;613:355–64.
 159. Haghani A, Li CZ, Robeck TR, Zhang J, Lu AT, Abulaeva J, Acosta-Rodríguez VA, Adams DM, Alagaili AN, Almunia J, et al. DNA methylation networks underlying mammalian traits. *Science.* 2023;381:5693.
 160. Seddon AR, Liao Y, Pace PE, Miller AL, Das AB, Kennedy MA, Hampton MB, Stevens AJ. Genome-wide impact of hydrogen peroxide on maintenance DNA methylation in replicating cells. *Epigenetics Chromatin.* 2021;14:17.
 161. Ye Q, Trivedi M, Zhang Y, Böhlke M, Alsulimani H, Chang J, Maher T, Deth R, Kim J. Brain iron loading impairs DNA methylation and alters GABAergic function in mice. *FASEB J.* 2019;33:2460–71.
 162. Qadir Nanakali NM, Maleki Dana P, Sadoughi F, Asemi Z, Sharifi M, Asemi R, Yousefi B. The role of dietary polyphenols in alternating DNA methylation in cancer. *Crit Rev Food Sci Nutr.* 2023;63:12256–69.
 163. Nowrasteh G, Zand A, Raposa LB, Szabó L, Tomes A, Molnár R, Kiss I, Orsós Z, Gerencsér G, Gyöngyi Z, Varjas T. Fruit extract, rich in polyphenols and flavonoids, modifies the expression of DNMT and HDAC genes involved in epigenetic processes. *Nutrients.* 2023;15:1867.
 164. Bazopoulou D, Knoefler D, Zheng Y, Ulrich K, Oleson BJ, Xie L, Kim M, Kaufmann A, Lee YT, Dou Y, et al. Developmental ROS individualizes organismal stress resistance and lifespan. *Nature.* 2019;576:301–5.
 165. Sato T, Greco CM. Expanding the link between circadian rhythms and redox metabolism of epigenetic control. *Free Radic Biol Med.* 2021;170:50–8.
 166. Hu T, Schreiter FC, Bagchi RA, Tatman PD, Hannink M, McKinsey TA. HDAC5 catalytic activity suppresses cardiomyocyte oxidative stress and NRF2 target gene expression. *J Biol Chem.* 2019;294:8640–52.
 167. Jänsch N, Meyners C, Muth M, Kopranovic A, Witt O, Oehme I, Meyer-Almes FJ. The enzyme activity of histone deacetylase 8 is modulated by a redox-switch. *Redox Biol.* 2019;20:60–7.
 168. Ou Y, Shen C, Chen Z, Liu T, Peng Y, Zong D, Ouyang R. TDP43/HDAC6/Prdx1 signaling pathway participated in the cognitive impairment of obstructive sleep apnea via regulating inflammation and oxidative stress. *Int Immunopharmacol.* 2024;127:111350.
 169. Yamaguchi K, Itakura M, Tsukamoto M, Lim SY, Uchida K. Natural polyphenols convert proteins into histone-binding ligands. *J Biol Chem.* 2022;298:102529.
 170. Russo GL, Vastolo V, Ciccarelli M, Albano L, Macchia PE, Ungaro P. Dietary polyphenols and chromatin remodeling. *Crit Rev Food Sci Nutr.* 2017;57:2589–99.
 171. Zhang Y, Qiao X, Liu L, Han W, Liu Q, Wang Y, Xie T, Tang Y, Wang T, Meng J, et al. Long noncoding RNA MAGI2-AS3 regulates the H(2)O(2) level and cell senescence via HSPA8. *Redox Biol.* 2022;54:102383.
 172. Xiao X, Xu M, Yu H, Wang L, Li X, Rak J, Wang S, Zhao RC. Mesenchymal stem cell-derived small extracellular vesicles mitigate oxidative stress-induced senescence in endothelial cells via regulation of miR-146a/Src. *Signal Transduct Target Ther.* 2021;6:354.
 173. Wang X, Yang J, Li H, Mu H, Zeng L, Cai S, Su P, Li H, Zhang L, Xiang W. miR-484 mediates oxidative stress-induced ovarian dysfunction and promotes granulosa cell apoptosis via SESN2 downregulation. *Redox Biol.* 2023;62:102684.

174. Diener C, Keller A, Meese E. Emerging concepts of miRNA therapeutics: from cells to clinic. *Trends Genet.* 2022;38:613–26.
175. Corrêa TA, Rogero MM. Polyphenols regulating microRNAs and inflammation biomarkers in obesity. *Nutrition.* 2019;59:150–7.
176. Wang X, Zhang S, Li Y, Zhang Y. The regulation of miRNAs using curcumin and other polyphenols during the prevention and treatment of Alzheimer's disease. *Hum Mol Genet.* 2025;34:117–27.
177. Wolff AM, Nango E, Young ID, Brewster AS, Kubo M, Nomura T, Sugahara M, Owada S, Barad BA, Ito K, et al. Mapping protein dynamics at high spatial resolution with temperature-jump X-ray crystallography. *Nat Chem.* 2023;15:1549–58.
178. Liu XR, Zhang MM, Gross ML. Mass spectrometry-based protein footprinting for higher-order structure analysis: fundamentals and applications. *Chem Rev.* 2020;120:4355–454.
179. Chen X, Cubillos-Ruiz JR. Endoplasmic reticulum stress signals in the tumour and its microenvironment. *Nat Rev Cancer.* 2021;21:71–88.
180. Chino H, Mizushima N. ER-phagy: quality control and turnover of endoplasmic reticulum. *Trends Cell Biol.* 2020;30:384–98.
181. Jin JK, Blackwood EA, Azizi K, Thuermer DJ, Fahem AG, Hofmann C, Kaufman RJ, Doroudgar S, Glembotski CC. ATF6 decreases myocardial ischemia/reperfusion damage and links ER stress and oxidative stress signaling pathways in the heart. *Circ Res.* 2017;120:862–75.
182. Schumann R, Bischoff E, Klaus S, Möhring S, Flock J, Keller S, Remans K, Ganter M, Deponte M. Protein abundance and folding rather than the redox state of Kelch13 determine the artemisinin susceptibility of *Plasmodium falciparum*. *Redox Biol.* 2021;48:102177.
183. Wu Y, Cui Z, Huang YH, de Veer SJ, Aralov AV, Guo Z, Moradi SV, Hinton AO, Deuis JR, Guo S, et al. Towards a generic prototyping approach for therapeutically-relevant peptides and proteins in a cell-free translation system. *Nat Commun.* 2022;13:260.
184. Poothong J, Pottakat A, Siirin M, Campos AR, Paton AW, Paton JC, Lagunas-Acosta J, Chen Z, Swift M, Volkman N, et al. Factor VIII exhibits chaperone-dependent and glucose-regulated reversible amyloid formation in the endoplasmic reticulum. *Blood.* 2020;135:1899–911.
185. Ming H, Li B, Jiang J, Qin S, Nice EC, He W, Lang T, Huang C. Protein degradation: expanding the toolbox to restrain cancer drug resistance. *J Hematol Oncol.* 2023;16:6.
186. Koopman MB, Ferrari L, Rüdiger SGD. How do protein aggregates escape quality control in neurodegeneration? *Trends Neurosci.* 2022;45:257–71.
187. Mollasalehi N, Francois-Moutal L, Porciani D, Burke DH, Khanna M. Aptamers targeting hallmark proteins of neurodegeneration. *Nucleic Acid Ther.* 2022;32:235–50.
188. Tsoi PS, Quan MD, Ferreón JC, Ferreón ACM. Aggregation of disordered proteins associated with neurodegeneration. *Int J Mol Sci.* 2023;24:3380.
189. Concha-Marambio L, Pritzkow S, Shah Nawaz M, Farris CM, Soto C. Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid. *Nat Protoc.* 2023;18:1179–96.
190. Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH, Villemagne VL, Aisen P, Vendruscolo M, Iwatsubo T, et al. The amyloid- β pathway in Alzheimer's Disease. *Mol Psychiatry.* 2021;26:5481–503.
191. Hallaceli E, Kayatekin C, Nazeen S, Wang XH, Sheinkopf Z, Sathyakumar S, Sarkar S, Jiang X, Dong X, Di Maio R, et al. The Parkinson's disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability. *Cell.* 2022;185:2035–2056.e2033.
192. Simuni T, Chahine LM, Poston K, Brumm M, Buracchio T, Campbell M, Chowdhury S, Coffey C, Concha-Marambio L, Dam T, et al. A biological definition of neuronal α -synuclein disease: towards an integrated staging system for research. *Lancet Neurol.* 2024;23:178–90.
193. Wang Z, Becker K, Donadio V, Siedlak S, Yuan J, Rezaei M, Incensi A, Kuzkina A, Orr CD, Tatsuoka C, et al. Skin α -synuclein aggregation seeding activity as a novel biomarker for Parkinson Disease. *JAMA Neurol.* 2020;78:1–11.
194. Viskupicova J, Rezarikova P. Natural polyphenols as SERCA activators: role in the endoplasmic reticulum stress-related diseases. *Molecules.* 2022;27:5095.
195. Zhu H, Gao M, Sun W, Liu H, Xu S, Li X. ROS/ER stress contributes to trimethyltin chloride-mediated hepatotoxicity; Tea polyphenols alleviate apoptosis and immunosuppression. *Comp Biochem Physiol C Toxicol Pharmacol.* 2023;263:109505.
196. Croce KR, Yamamoto A. Dissolving the complex role aggregation plays in neurodegenerative disease. *Mov Disord.* 2021;36:1061–9.
197. Cox D, Raeburn C, Sui X, Hatters DM. Protein aggregation in cell biology: an aggregomics perspective of health and disease. *Semin Cell Dev Biol.* 2020;99:40–54.
198. Ayers JL, Prusiner SB. Prion protein—mediator of toxicity in multiple proteinopathies. *Nat Rev Neurol.* 2020;16:187–8.
199. Kingwell K. Tackling TDP43 proteinopathies. *Nat Rev Drug Discov.* 2023;22:354.
200. Baughn MW, Melamed Z, López-Erauskin J, Beccari MS, Ling K, Zuberi A, Presa M, Gonzalo-Gil E, Maimon R, Vazquez-Sanchez S, et al. Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies. *Science.* 2023;379:1140–9.
201. van Dam L, Dansen TB. Cross-talk between redox signalling and protein aggregation. *Biochem Soc Trans.* 2020;48:379–97.
202. Zhao X, Lorent K, Escobar-Zarate D, Rajagopalan R, Loomes KM, Gillespie K, Mesaros C, Estrada MA, Blair IA, Winkler JD, et al. Impaired redox and protein homeostasis as risk factors and therapeutic targets in toxin-induced biliary atresia. *Gastroenterology.* 2020;159:1068–1084.e1062.
203. Heo AJ, Ji CH, Kwon YT. The Cys/N-degron pathway in the ubiquitin-proteasome system and autophagy. *Trends Cell Biol.* 2023;33:247–59.
204. Kim J, Byun I, Kim DY, Joh H, Kim HJ, Lee MJ. Targeted protein degradation directly engaging lysosomes or proteasomes. *Chem Soc Rev.* 2024;53:3253–72.
205. Li B, Ming H, Qin S, Zhou L, Huang Z, Jin P, Peng L, Luo M, Zhang T, Wang K, et al. HSPA8 activates Wnt/ β -catenin signaling to facilitate BRAF V600E colorectal cancer progression by CMA-Mediated CAV1 Degradation. *Adv Sci (Weinh).* 2024;11:e2306535.
206. Kolla S, Ye M, Mark KG, Rapé M. Assembly and function of branched ubiquitin chains. *Trends Biochem Sci.* 2022;47:759–71.
207. Cowan AD, Ciulli A. Driving E3 ligase substrate specificity for targeted protein degradation: lessons from nature and the laboratory. *Annu Rev Biochem.* 2022;91:295–319.
208. Nargeh H, Aliabadi F, Ajami M, Pazoki-Toroudi H. Role of polyphenols on gut microbiota and the ubiquitin-proteasome system in neurodegenerative diseases. *J Agric Food Chem.* 2021;69:6119–44.
209. Gu W, Wu G, Chen G, Meng X, Xie Z, Cai S. Polyphenols alleviate metabolic disorders: the role of ubiquitin-proteasome system. *Front Nutr.* 2024;11:1445080.
210. Leri M, Bertolini A, Stefani M, Bucciantini M. EVOO polyphenols relieve synergistically autophagy dysregulation in a cellular model of Alzheimer's Disease. *Int J Mol Sci.* 2021;22:7225.
211. Bianchi VE, Rizzi L, Soma F. The role of nutrition on Parkinson's disease: a systematic review. *Nutr Neurosci.* 2023;26:605–28.
212. Acharya A, Vishwas S, Singh SK. Combination therapy of mitochondria-targeted antioxidants and polyphenols for early intervention in Huntington's disease. *EXCLI J.* 2025;24:179–80.
213. Laha D, Sarkar J, Maity J, Pramanik A, Howlader MSI, Barthels D, Das H. Polyphenolic compounds inhibit osteoclast differentiation while reducing autophagy through limiting ROS and the mitochondrial membrane potential. *Biomolecules.* 2022;12:1220.
214. Hseu YC, Vudhya Gowrisankar Y, Wang LW, Zhang YZ, Chen XZ, Huang PJ, Yen HR, Yang HL. The in vitro and in vivo depigmenting activity of pterostilbene through induction of autophagy in melanocytes and inhibition of UVA-irradiated α -MSH in keratinocytes via Nrf2-mediated antioxidant pathways. *Redox Biol.* 2021;44:102007.
215. Moujalled D, Strasser A, Liddell JR. Molecular mechanisms of cell death in neurological diseases. *Cell Death Differ.* 2021;28:2029–44.
216. Kayagaki N, Webster JD, Newton K. Control of cell death in health and disease. *Annu Rev Pathol.* 2024;19:157–80.
217. Czabotar PE, Garcia-Saez AJ. Mechanisms of BCL-2 family proteins in mitochondrial apoptosis. *Nat Rev Mol Cell Biol.* 2023;24:732–48.
218. Xue Y, Morris JL, Yang K, Fu Z, Zhu X, Johnson F, Meehan B, Witkowski L, Yasmeen A, Golenar T, et al. SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca^{2+} flux to mitochondria. *Nat Commun.* 2021;12:5404.
219. Zheng X, Li W, Xu H, Liu J, Ren L, Yang Y, Li S, Wang J, Ji T, Du G. Sinomenine ester derivative inhibits glioblastoma by inducing mitochondria-dependent apoptosis and autophagy by PI3K/AKT/mTOR and AMPK/mTOR pathway. *Acta Pharm Sin B.* 2021;11:3465–80.

220. Liang J, Cao R, Wang X, Zhang Y, Wang P, Gao H, Li C, Yang F, Zeng R, Wei P, et al. Mitochondrial PKM2 regulates oxidative stress-induced apoptosis by stabilizing Bcl2. *Cell Res.* 2017;27:329–51.
221. Cosentino K, Hertlein V, Jenner A, Dellmann T, Gokjovic M, Peña-Blanco A, Dadsena S, Wajngarten N, Danial JSH, Thevathasan JV, et al. The interplay between BAX and BAK tunes apoptotic pore growth to control mitochondrial-DNA-mediated inflammation. *Mol Cell.* 2022;82:933–949. e939.
222. Quarato G, Mari L, Barrows NJ, Yang M, Ruehl S, Chen MJ, Guy CS, Low J, Chen T, Green DR. Mitophagy restricts BAX/BAK-independent, Parkin-mediated apoptosis. *Sci Adv.* 2023;9:8156.
223. Li S, Li H, Zhang YL, Xin QL, Guan ZQ, Chen X, Zhang XA, Li XK, Xiao GF, Lozach PY, et al. SFTSV infection induces BAK/BAX-dependent mitochondrial DNA release to trigger NLRP3 inflammasome activation. *Cell Rep.* 2020;30:4370–4385.e4377.
224. Fang Y, Duan C, Chen S, Liu Z, Jiang B, Ai W, Wang L, Xie P, Fang H. Tanshinone-IIA inhibits myocardial infarct via decreasing of the mitochondrial apoptotic signaling pathway in myocardiocytes. *Int J Mol Med.* 2021;48:158.
225. Ai X, Yu P, Luo L, Sun J, Tao H, Wang X, Meng X. Berberis dictyophylla F. inhibits angiogenesis and apoptosis of diabetic retinopathy via suppressing HIF-1 α /VEGF/DLL-4/Notch-1 pathway. *J Ethnopharmacol.* 2022;296:115453.
226. King AP, Wilson JJ. Endoplasmic reticulum stress: an arising target for metal-based anticancer agents. *Chem Soc Rev.* 2020;49:8113–36.
227. Morris HE, Neves KB, Nilsen M, Montezano AC, MacLean MR, Touyz RM. Notch3/Hes5 induces vascular dysfunction in hypoxia-induced pulmonary hypertension through ER stress and redox-sensitive pathways. *Hypertension.* 2023;80:1683–96.
228. Zhou Z, Fan Y, Zong R, Tan K. The mitochondrial unfolded protein response: a multitasking giant in the fight against human diseases. *Ageing Res Rev.* 2022;81:101702.
229. Ren J, Bi Y, Sowers JR, Hetz C, Zhang Y. Endoplasmic reticulum stress and unfolded protein response in cardiovascular diseases. *Nat Rev Cardiol.* 2021;18:499–521.
230. He Y, Zheng Z, Liu C, Li W, Zhao L, Nie G, Li H. Inhibiting DNA methylation alleviates cisplatin-induced hearing loss by decreasing oxidative stress-induced mitochondria-dependent apoptosis via the LRP1-P13K/AKT pathway. *Acta Pharm Sin B.* 2022;12:1305–21.
231. Liu W, Xu L, Wang X, Zhang D, Sun G, Wang M, Wang M, Han Y, Chai R, Wang H. PRDX1 activates autophagy via the PTEN-AKT signaling pathway to protect against cisplatin-induced spiral ganglion neuron damage. *Autophagy.* 2021;17:4159–81.
232. Wei Y, Miao Q, Zhang Q, Mao S, Li M, Xu X, Xia X, Wei K, Fan Y, Zheng X, et al. Aerobic glycolysis is the predominant means of glucose metabolism in neuronal somata, which protects against oxidative damage. *Nat Neurosci.* 2023;26:2081–9.
233. Lavigne EG, Cavagnino A, Steinschneider R, Breton L, Baraibar MA, Jäger S. Oxidative damage prevention in human skin and sensory neurons by a salicylic acid derivative. *Free Radic Biol Med.* 2022;181:98–104.
234. Angelova PR. Sources and triggers of oxidative damage in neurodegeneration. *Free Radic Biol Med.* 2021;173:52–63.
235. Trudler D, Nazor KL, Eisele YS, Grabauskas T, Dolatabadi N, Parker J, Sultan A, Zhong Z, Goodwin MS, Levites Y, et al. Soluble α -synuclein-antibody complexes activate the NLRP3 inflammasome in hiPSC-derived microglia. *Proc Natl Acad Sci U S A.* 2021. <https://doi.org/10.1073/pnas.2025847118>.
236. Song LL, Qu YQ, Tang YP, Chen X, Lo HH, Qu LQ, Yun YX, Wong VKW, Zhang RL, Wang HM, et al. Hyperoside alleviates toxicity of β -amyloid via endoplasmic reticulum-mitochondrial calcium signal transduction cascade in APP/PS1 double transgenic Alzheimer's disease mice. *Redox Biol.* 2023;61:102637.
237. González-Rodríguez P, Zampese E, Stout KA, Guzman JN, Ilijic E, Yang B, Tkatch T, Stavarche MA, Wokosin DL, Gao L, et al. Disruption of mitochondrial complex I induces progressive parkinsonism. *Nature.* 2021;599:650–6.
238. Wang ZL, Yuan L, Li W, Li JY. Ferroptosis in Parkinson's disease: glia-neuron crosstalk. *Trends Mol Med.* 2022;28:258–69.
239. Lossi L, Merighi A, Novello V, Ferrandino A. Protective effects of some grapevine polyphenols against naturally occurring neuronal death. *Molecules.* 2020;25:2925.
240. Zhou ZD, Xie SP, Saw WT, Ho PGH, Wang H, Lei Z, Yi Z, Tan EK. The therapeutic implications of tea polyphenols against Dopamine (DA) neuron degeneration in Parkinson's Disease (PD). *Cells.* 2019;8:911.
241. Chandrasekaran V, Hediyaal TA, Anand N, Kendaganana PH, Gorantla VR, Mahalakshmi AM, Ghanekar RK, Yang J, Sakthar MK, Chidambaram SB. Polyphenols, autophagy and neurodegenerative diseases: a review. *Biomolecules.* 2023;13:1196.
242. Di Lorenzo C, Colombo F, Biella S, Stockley C, Restani P. Polyphenols and human health: the role of bioavailability. *Nutrients.* 2021;13:273.
243. Rostamabadi H, Bajaj D, Demirkesen I, Kumar Y, Su C, Wang Y, Nowacka M, Singha P, Falsafi SR. Starch modification through its combination with other molecules: gums, mucilages, polyphenols and salts. *Carbohydr Polym.* 2023;314:120905.
244. Aatif M. Current understanding of polyphenols to enhance bioavailability for better therapies. *Biomedicines.* 2023;11:2078.
245. Li X, Meng X, de Leeuw TC, Te Poele EM, Pijning T, Dijkhuizen L, Liu W. Enzymatic glucosylation of polyphenols using glucanases and branching sucraes of glycoside hydrolase family 70. *Crit Rev Food Sci Nutr.* 2023;63:5247–67.
246. Jia Y, Cai S, Muhoza B, Qi B, Li Y. Advance in dietary polyphenols as dipeptidyl peptidase-IV inhibitors to alleviate type 2 diabetes mellitus: aspects from structure-activity relationship and characterization methods. *Crit Rev Food Sci Nutr.* 2023;63:3452–67.
247. Polia F, Pastor-Belda M, Martínez-Blázquez A, Horcjada MN, Tomás-Barberán FA, García-Villalba R. Technological and biotechnological processes to enhance the bioavailability of dietary (poly)phenols in humans. *J Agric Food Chem.* 2022;70:2092–107.
248. Rocchetti G, Giuberti G, Lucchini F, Lucini L. Polyphenols and sesquiterpene lactones from artichoke heads: modulation of starch digestion, gut bioaccessibility, and bioavailability following in vitro digestion and large intestine fermentation. *Antioxidants (Basel).* 2020;9:306.
249. Contente ML, Annunziata F, Cannazza P, Donzella S, Pinna C, Romano D, Tamborini L, Barbosa FG, Molinari F, Pinto A. Biocatalytic approaches for an efficient and sustainable preparation of polyphenols and their derivatives. *J Agric Food Chem.* 2021;69:13669–81.
250. Yan S, Yao Y, Xie X, Zhang S, Huang Y, Zhu H, Li Y, Qi B. Comparison of the physical stabilities and oxidation of lipids and proteins in natural and polyphenol-modified soybean protein isolate-stabilized emulsions. *Food Res Int.* 2022;162:112066.
251. Petrella C, Di Certo MG, Gabanella F, Barbato C, Ceci FM, Greco A, Ralli M, Polimeni A, Angeloni A, Severini C, et al. Mediterranean diet, brain and muscle: olive polyphenols and resveratrol protection in neurodegenerative and neuromuscular disorders. *Curr Med Chem.* 2021;28:7595–613.
252. Casamenti F, Stefani M. Olive polyphenols: new promising agents to combat aging-associated neurodegeneration. *Expert Rev Neurother.* 2017;17:345–58.
253. Yan X, Zeng Z, McClements DJ, Gong X, Yu P, Xia J, Gong D. A review of the structure, function, and application of plant-based protein-phenolic conjugates and complexes. *Compr Rev Food Sci Food Saf.* 2023;22:1312–36.
254. Méndez L, Medina I. Polyphenols and fish oils for improving metabolic health: a revision of the recent evidence for their combined nutraceutical effects. *Molecules.* 2021;26:2438.
255. Milenkovic D, Ruskovska T. Mechanistic insights into dietary (poly)phenols and vascular dysfunction-related diseases using multi-omics and integrative approaches: machine learning as a next challenge in nutrition research. *Mol Aspects Med.* 2023;89:101101.
256. Chang PR, Liou JW, Chen PY, Gao WY, Wu CL, Wu MJ, Yen JH. The neuroprotective effects of flavonoid fisetin against corticosterone-induced cell death through modulation of ERK, p38, and PI3K/Akt/FOXO3a-dependent pathways in PC12 Cells. *Pharmaceutics.* 2023;15:2376.
257. Iqbal A, Ahmed M, Iqbal MK, Pottot FH, Haque SE. Polyphenols as potential therapeutics for pain and inflammation in spinal cord injury. *Curr Mol Pharmacol.* 2021;14:714–30.
258. Ziegler T, Tsiountsioura M, Meixner-Goetz L, Cvirn G, Lamprecht M. Polyphenols' impact on selected biomarkers of brain aging in healthy middle-aged and elderly subjects: a review of clinical Trials. *Nutrients.* 2023;15:3770.
259. De Nicoló S, Tarani L, Ceccanti M, Maldini M, Natella F, Vania A, Chaldakov GN, Fiore M. Effects of olive polyphenols administration on nerve

- growth factor and brain-derived neurotrophic factor in the mouse brain. *Nutrition*. 2013;29:681–7.
260. Liao Y, Mai X, Wu X, Hu X, Luo X, Zhang G. Exploring the inhibition of quercetin on acetylcholinesterase by multispectroscopic and in silico approaches and evaluation of its neuroprotective effects on PC12 cells. *Molecules*. 2022;27:7971.
 261. Tabrez S, Jabir NR, Adhami VM, Khan MI, Moulay M, Kamal MA, Mukhtar H. Nanoencapsulated dietary polyphenols for cancer prevention and treatment: successes and challenges. *Nanomedicine (Lond)*. 2020;15:1147–62.
 262. Xie J, Shen Z, Anraku Y, Kataoka K, Chen X. Nanomaterial-based blood-brain-barrier (BBB) crossing strategies. *Biomaterials*. 2019;224:119491.
 263. Zhu Z, Liao L, Qiao HJA, Medicine H. Extracellular vesicle-based drug delivery system boosts phytochemicals' therapeutic effect for neurodegenerative diseases. *Accupunctre Herb Med*. 2022;2:229–39.
 264. Liu R, Liu Z, Guo X, Kebebe D, Pi J, Guo PJA, Medicine H. Construction of curcumin-loaded micelles and evaluation of the anti-tumor effect based on angiogenesis. *Accupunctre Herb Med*. 2023;3:343–56.
 265. Ming H, Li B, Tian H, Qin S, Zhang T, Liu S, Gao Y, Yang C, Chen L. Ni JJCEJ: Copper-coordinated self-assembly nanogels for efficient cancer immunotherapy by synergistic suppression of tumor-infiltrating regulatory T cells. *Chem Eng J*. 2024;500:157288.
 266. Zhang Z, Li X, Sang S, McClements DJ, Chen L, Long J, Jiao A, Jin Z, Qiu C. Polyphenols as plant-based nutraceuticals: health effects, encapsulation, nano-delivery, and application. *Foods*. 2022;11:2189.
 267. Huang X, He T, Liang X, Xiang Z, Liu C, Zhou S, Luo R, Bai L, Kou X. Li XJMo: Advances and applications of nanoparticles in cancer therapy. *Cancer*. 2024;3:e67.
 268. Bhise K, Kashaw SK, Sau S, Iyer AK. Nanostructured lipid carriers employing polyphenols as promising anticancer agents: quality by design (QbD) approach. *Int J Pharm*. 2017;526:506–15.
 269. Mirchandani Y, Patravale VB, S B: Solid lipid nanoparticles for hydrophilic drugs. *J Control Release*. 2021;335:457–64.
 270. Dilliard SA, Siegwart DJ. Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs. *Nat Rev Mater*. 2023;8:282–300.
 271. Zhang W, Mehta A, Tong Z, Esser L, Voelcker NH. Development of polymeric nanoparticles for blood-brain barrier transfer-strategies and challenges. *Adv Sci (Weinh)*. 2021;8:2003937.
 272. Yuan T, Wang T, Zhang J, Liu P, Xu J, Gu Z, Xu J, Li Y. Robust and multifunctional nanoparticles assembled from natural polyphenols and metformin for efficient spinal cord regeneration. *ACS Nano*. 2023;17:18562–75.
 273. Qiao R, Fu C, Forgham H, Javed I, Huang X, Zhu J, Whittaker AK, Davis TP. Magnetic iron oxide nanoparticles for brain imaging and drug delivery. *Adv Drug Deliv Rev*. 2023;197:114822.
 274. Zhang F, Lu G, Wen X, Li F, Ji X, Li Q, Wu M, Cheng Q, Yu Y, Tang J, Mei L. Magnetic nanoparticles coated with polyphenols for spatio-temporally controlled cancer photothermal/immunotherapy. *J Control Release*. 2020;326:131–9.
 275. Fan Y, Zhang Y, Peng C, Chang X, Sun L, Kong XJ, Zhang BZ, Dong LY, Wang XH. Preparation of teamed boronate affinity magnetic nanoparticles for extraction of polyphenols from Flos Lonicerae Beverage under neutral pH prior to their determination by high-performance liquid chromatography-mass spectrometry. *J Chromatogr A*. 2020;1619:460913.
 276. Chen Y, Luo R, Li J, Wang S, Ding J, Zhao K, Lu B, Zhou W. Intrinsic radical species scavenging activities of tea polyphenols nanoparticles block pyroptosis in endotoxin-induced sepsis. *ACS Nano*. 2022;16:2429–41.
 277. Mei H, Gao Z, Zhao K, Li M, Ashokkumar M, Song A, Cui J, Caruso F, Hao J. Sono-fenton chemistry converts phenol and phenyl derivatives into polyphenols for engineering surface coatings. *Angew Chem Int Ed Engl*. 2021;60:21529–35.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.